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ABSTRACT 
 
Rachel Marie Bleich: Bacillus as a Heterologous Platform for Peptide Drug Discovery 
(Under the direction of Albert A. Bowers) 
 
 
 
 The rising incidence of resistance to current antibiotics has become one of the world’s 
leading health problems.  Nationally, at least 2 million people are infected with antibiotic-
resistant bacteria, and there are over 23,000 deaths each year from antibiotic resistant 
infections. Natural products are a rich source of novel compounds for antibiotic development 
that can help circumvent antibiotic resistance.  Bacteria have already selectively developed 
these molecules for that very purpose.  At subinhibitory concentrations, natural product 
antibiotics can cause developmental and physiological responses in bacteria. This research 
focuses on harnessing the biosynthetic potential of one bacterial genus, Bacillus, to discover 
new antibiotic natural products and understand the broader roles these compounds play in 
bacterial communication. 
We use a combination of coculture, fluorescent transcriptional reporter assays, and 
MALDI-TOF IMS to identify and characterize the thiocillins and the broader thiopeptide 
family as chemical signals that induce biofilm formation in Bacillus subtilis.  Biofilm 
production is an important bacterial defense. We probe into the mechanism of this thiocillin 
signaling activity in relation to antibiosis.  
We further pursue an intensive bioinformatics analysis of genus Bacillus to measure 
its chemical diversity and better understand the role of its specialized metabolites. We 
 iv 
uncovered the biosynthetic machinery for a set of highly-conserved compounds across the 
Bacillus genus that play either known or currently unknown roles in signaling and bacterial 
development within Bacilli. We ascribe a signaling role to the highly-conserved alkylpyrone 
biosynthesis pathway in Bacillus. Additionally, we identify a number of unique, weakly 
conserved natural product biosynthesis pathways scattered across all species. The unique 
pathways offer leads for identifying new, distinct natural products that could exhibit 
previously unknown biological activities.  
To access the new pathways we identify in our bioinformatics analysis, we develop a 
heterologous expression platform that would allow us to rapidly move entire biosynthetic 
pathways into the host organism, Bacillus subtilis. Using a Bacillus based platform allows for 
rapid cloning and expression of peptides, and circumvents many challenges in the field. We 
develop tools that will enable future efforts to discover, characterize, and modify natural 
product antibiotics in Bacillus subtilis. 
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CHAPTER I  
INTRODUCTION 
 
The rising incidence of resistance to current antibiotics has become one of the world’s 
leading health problems: new antibiotics are desperately needed for the treatment of 
infectious disease.  Nationally, at least 2 million people are infected with antibiotic-resistant 
bacteria, and there are over 23,000 deaths each year from antibiotic resistant infections (1).  
Worldwide, the number of deaths caused by resistant infections is closer to 700,000 (2). 
According to the CDC, 250,000 infections and 14,000 deaths are caused by Clostridium 
difficile infection, alone (3).  The most devastating resistant microbes are most commonly 
discovered in healthcare facilities where exposure to antibiotics allow bacteria to develop 
resistance.  Healthcare-associated infections (HAIs) cause 1.7 million infections and 99,000 
deaths each year in the United States, in addition to $28-33 billion in excess costs (4–6).  In 
North Carolina alone, HAIs cost $124-348 million annually (6).  One reason bacteria are able 
to survive in healthcare facilities is through formation of biofilms on medical devices, which 
allow infection to spread (7).  Biofilms, an extracellular matrix produced by bacteria growing 
on surfaces, are a natural defense for bacteria that allows them to withstand antibiotic 
treatment (8, 9).  Thus, allowing them to survive, gain resistance, and cause further 
infections. Microbes are gaining resistance to even the ‘last resort’ antibiotics, which are 
some of the only options left for certain infections (2, 10, 11).  Reports of resistance to last 
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resort antibiotics, such as the carbapenems and colistin, have been emerging around the 
world (2, 12). 
 Antibiotic resistance has spread rapidly through the overuse of antibiotics, both in the 
clinic and in the environment (3, 13, 14).  Many factory farms commonly give antibiotics to 
livestock to prevent disease and promote growth.  However, this leads animals to gain 
resistant microbes that can be spread to humans.  North Carolina is the second highest pork 
producer in the country.  Many NC farms treat hogs with antibiotics, which at least one study 
has shown leads to higher rates of resistant Staphylococcus aureus that can be spread to 
workers and communities (15).  Over-prescription in the clinic is another major factor in the 
spread of antibiotic resistance.  As much as half of the antibiotics prescribed are unnecessary, 
leading to excessive antibiotic exposure on human microbes (3).   
This has led to continuously smaller pools of antibiotics to choose from to combat 
drug-resistant infections.  There has also been a lack of new antibiotics to make it into the 
drug development pipeline.  In the last thirty years, no new classes of antibiotics have been 
discovered (12).  Additionally, pharmaceutical and biotechnology companies are leaving the 
arena of antibiotic discovery, focusing on drug development programs that bring a better 
return on investment (16).  Antibiotic drug development is also challenging due to the unique 
properties needed for these compounds: they must be able to penetrate bacterial cell walls 
(especially difficult for Gram-negative bacteria) without any effect on human cells (12, 16–
18).  Finally, after decades of antibiotic research, the low-hanging fruit of antimicrobial 
therapeutics has already been discovered through high-throughput screens and natural 
products isolations (16).  New sources, methods, and efforts are needed to identify novel 
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classes of antibiotics that will have new mechanisms of action that are less-likely to cause 
resistance.   
 
1.1 Biosynthesis of natural products 
Advances in genome sequencing have greatly increased our knowledge of the 
untapped potential for new antibiotics produced by bacteria (19–21).  The natural grouping of 
genes in bacterial genomes (biosynthetic gene clusters or BGCs) allows rapid identification 
of new pathways that could yield new antibiotic natural products (22, 23).  Bacteria produce 
a variety of natural products that are biosynthesized through several different types of 
pathways.  Most of the natural products used as antibiotics are synthesized through these 
routes.  This includes the larger assembly line pathways, non-ribosomal peptide synthetases 
(NRPS) and polyketide synthases (PKS), and the smaller ribosomally-synthesized and post-
translationally modified peptides (RiPPs) pathways. 
Polyketide synthases (PKS) are an important class of natural product antibiotics that 
form the bases for nearly one third of pharmaceutics (24), some of the most famous examples 
include the antibiotics, erythromycin and tetracycline, and the antifungal, lovastatin (25).  
PKS natural products are synthesized on a multimodular synthase in an assembly-line fashion 
using malonyl, methylmalonyl, and acetyl-CoA building blocks (24, 25).  Each module in the 
synthase contains an acyl carrier protein (ACP), ketosynthase (KS), and acyltransferase (AT) 
domains that act to build a growing carbon chain from the building blocks through Claisen 
condensation reactions (24, 26).  The AT loads a building block on to the 
phosphopantetheine arm of the ACP, while the KS catalyzes the reaction between the 
building block and the intermediate from the upstream module.  Other domains in the module 
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can make further modifications, including ketoreductases (KR), dehydratases (DH), or 
enoylreductases (ER) (24, 26, 27).  These various modifications help give PKSs their diverse 
structures (26). 
Non-ribosomal peptide synthetases (NRPS) are biosynthesized in an assembly line 
fashion, similar to PKS.  They are also an important class of natural product antibiotics, some 
of the most famous examples include the antibiotics penicillin, gramicidin, and daptomycin 
(27, 28).  NRPS are distinct from PKS in the fact that they use amino acid building blocks 
and a different range of modifying domains.  Each module in the synthetase contains 
adenylation (A), condensation (C), and peptidyl carrier protein (PCP) domains that build the 
peptide chain with modifications from methyltransferase, epimerase, heterocyclization, and 
oxidation domains (27, 28).  The A domain activates and transfers the amino acid building 
block on to the phosphopantetheine arm of the PCP in an ATP-dependent manner (27).  The 
PCP transports it to the C domain for peptide bond formation on to the growing peptide chain 
(27, 28).  NRPS can be quite diverse based on amino acid building blocks and their 
modifications.   
 The ribosomally-synthesized and post-translationally modified peptides (RiPPs) 
biosynthetic pathways are unique compared to the mulitmodular megasenzymes of the NRPS 
and PKS pathways.  RiPPs have a structural gene that encodes a precursor peptide, which 
will become the final natural product (29).  The precursor peptide is translated by the 
ribosome and then post-translationally modified by other biosynthetic enzymes in the 
pathway (Figure 1.1) (29).  These modifications help to install unique functional groups and 
confer specific structures to these diverse natural products.  RiPPs are advantageous because 
they can be genetically manipulated to produce mutant compounds.  The precursor peptide 
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has two components: leader peptide and core peptide portions (29, 30).  The core peptide 
becomes the final natural product, while the leader peptide is recognized by the post-
translationally modifying enzymes and helps guide the core peptide through biosynthesis 
(Figure 1.1) (30).  By modifying the core sequence while maintaining the leader sequence, 
modified RiPPs are easily produced. 
  
 
Figure 1.1. Biosynthesis of ribosomally-synthesized and post-translationally modified 
peptides (RiPPs). The leader peptide guides the core peptide through biosynthesis to become 
the final natural product. 
 
1.2 Natural products as antibiotics and signaling molecules 
Natural products are a rich source of novel compounds for antibiotic development 
that can help circumvent antibiotic resistance (18, 31–33).  Bacteria have already selectively 
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developed these molecules for that very purpose.  A recent Pew Report identified natural 
products as an important source for new antibiotic classes because of their unique, evolved 
structures (12).  Microbes have developed their own set of compounds as an antibiotic 
arsenal to promote their own survival in competition for resources.  Natural products are 
evolved to be effective against other bacteria (16).  Additionally, natural products tend to 
have more complex structures and chemistries that what can easily be accessed synthetically.  
The molecules fall outside of the chemical properties usually associated with lead small 
molecule compounds (33). Finding methods to reliably accessing these potential antibiotics is 
still a major challenge.  Many of these biosynthetic gene clusters are  transcriptionally silent 
when their host organism is grown under laboratory conditions, or many host organisms are 
unable to be grown using standard laboratory procedures (34–39).  Developing tools to 
reliably and robustly identify, prioritize, access, and characterize natural product biosynthetic 
pathways is crucial for antibiotic development. 
Beyond their antibiotic properties, natural products also play important roles as 
signaling molecules in bacterial communication (40–43).  At subinhibitory concentrations,  
natural product antibiotics can cause developmental and physiological responses in bacteria, 
including affecting quorum sensing, virulence factor production, or biofilm production (44–
48), which is a general bacterial defense mechanism (49) (Figure 1.2).  In some cases, this 
activity has been linked to the mechanism of action of the antibiotic.  For instance, the 
aminoglycoside tobramycin induces quorum-sensing via inhibition of translation of the 
RhlI/R system components (50).   
Bacilli can also transition into a dormant state through sporulation as part of its 
lifecycle, with most environmental cells surviving as spores (51).  Additionally, Bacilli can 
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leave their dormant, spore state and germinate to begin actively growing in response to 
favorable conditions (52).  These various states of Bacillus development and cellular 
differentiation are mediated through responses to natural product metabolites (52, 53) 
(Figure 1.2).  In subsequent chapters, we will ascribe signaling roles to known and new 
Bacillus natural products.  It is important to study the role these natural products play in their 
native environments as mediators of bacterial communication to more fully understand their 
biological activities.  Through this process, we gain more insight into the mechanisms of the 
antibiotics we are developing. 
 
Figure 1.2. Natural product antibiotics can function as signals to affect bacterial 
development.  Figure modified from Shank, EA & Kolter, R (53). 
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Bacteria devote large portions of their genomes to producing this array of natural 
products.  These structurally complex molecules are evolved to function in specific roles that 
benefit the producing bacteria.  Whether this is as an antibiotic to confer a fitness advantage 
or as a specialized metabolite that affects bacterial development, these natural products are 
important chemical cues in bacterial processes.  With selective pressure so great, it is no 
surprise that these microorganisms have developed methods to evade the effects of natural 
product antibiotics, leading to resistance. 
 
1.3 Bacillus natural products 
We focused our efforts on developing a platform to study natural product biosynthetic 
pathways from the underexplored bacterial genus, Bacillus.  These Gram-positive organisms 
are present across soils, in the plant rhizosphere, and even in the gastrointestinal tracts of 
insects, animals, and humans (54–56).  The Bacillus species are diverse, with some used as 
plant-growth-promoting bacteria or food additives, while others are pathogens (54, 55).   The 
causative agent of anthrax, Bacillus anthracis, belongs to this genus alongside Bacillus 
subtilis, which is widely used in industry (57).  Additionally, some Bacilli are already known 
to be prolific natural product producers (54, 58).  Some of which have antibiotic and 
antifungal activities.  Probably the most famous example of a therapeutically-used antibiotic 
produced by a Bacillus species is the compound bacitracin (59, 60) (Figure 1.3).  Bacitracin 
is used topically as an antibiotic, and is one of the active ingredients of Neosporin (Figure 
1.3).   
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Figure 1.3. Bacitracin is the most famous Bacillus natural product antibiotic in use. 
 
In this work, we focus on studying the biosynthetic potential of one understudied 
bacterial genus, Bacillus.  We look for natural products that would impact biofilm formation 
in our model organism, Bacillus subtilis, and discover that the RiPP, thiocillin, induces B. 
subtilis to produce biofilm.  Bacillus subtilis is a model organism that is related to the 
pathogen, Clostridium difficile, a major cause of healthcare-associate infections.  
Additionally, we wanted to look more broadly at the overall biosynthetic potential of the 
genus.  We did extensive bioinformatics analysis of over 1,500 Bacillus genomes, and 
uncovered a core set of conserved, known natural product biosynthetic pathways that are 
important for signaling in Bacillus development.  We were also able to discover a set of 
highly-conserved pathways whose products are unknown, and that we hypothesize are 
important to Bacilli.  Lastly, we also identified unknown, unique biosynthetic pathways that 
are promising leads to discovering natural products with new structures.  To access these new 
pathways, we developed a heterologous expression platform that allows us to rapidly move 
entire biosynthetic pathways into the host organisms, Bacillus subtilis.  We made 
Bacitracin 
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modifications to B. subtilis to improve its genetic competence, developed a direct cloning 
approach using Gibson assembly, and repurposed the machinery to do unnatural amino acid 
incorporation in Bacillus subtilis. 
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CHAPTER II 
THIOPEPTIDE ANTIBIOTICS STIMULATE BIOFILM FORMATION IN 
BACILLUS SUBTILIS 
2.1 Introduction 
 Natural products have been essential as antibiotics for combating infectious disease.  
However, these compounds, also called secondary or specialized metabolites, are being 
increasingly recognized for their secondary effects as signaling molecules in bacterial 
communication (1–7).   At subinhibitory concentrations, natural product antibiotics can cause 
developmental and physiological responses in bacteria (8, 9). We are particularly interested 
in studying natural product signals in the well-characterized developmental process bacteria 
go through when they produce biofilm.   We use the model organism, Bacillus subtilis, to 
study biofilm formation, as it has well-characterized and well-defined developmental states 
(10).   
 Biofilms are communities of tightly associated bacterial cells encased by an 
extracellular matrix that can form on either a liquid or solid surface (11).  The extracellular 
matrix has three main components, an exopolysaccharide component that is the product of 
the epsA-O operon, anchoring proteins and amyloid fibers encoded by the products of the 
tapA operon, and the secreted protein BslA, which is important for surface hydrophobicity 
(12–14).  Biofilms can be beneficial, especially for protecting plants by forming on plant 
roots (15–17), or harmful, especially for increasing antibiotic resistance by forming on 
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medical devices or during infections (18, 19). Forming biofilms can be a general defense 
mechanism against competitors (20, 21).  Further understanding the natural product signals 
that affect biofilm formation is important for studying bacterial communication and how 
natural product antibiotics may affect the bacteria they come into contact with. 
 In certain bacteria, biofilm formation results from bacteria developing into 
transcriptionally distinct cells (22, 10, 23). Bacillus subtilis, has well defined cellular 
differentiation states that can be utilized for studying biofilm formation (10).  These different 
transcriptional states are regulated by the master regulator, Spo0A, whose phosphorylation 
state drives regulation of downstream transcriptional cell fates (10, 13).  When Spo0A is at a 
lower phosphorylation level it differentiates into a transcriptional state leading to biofilm 
formation (12).  However at higher levels of phosphorylation, Spo0A drives differentiation in 
a sporulation cell fate (12).  The phosphorylation of Spo0A is regulated by five sensor 
histidine kinases (KinA, KinB, KinC, KinD, KinE) either directly or through a phosphorelay 
(10, 13).  Spo0A governs the regulation of biofilm-matrix gene expression through the 
regulators, SinR and AbrB, that repress both the epsA-O and tapA operons (13).  AbrB also 
works to repress matrix protein, BslA, in addition to both the espA-O and tapA operons (13).
 We can use this knowledge to develop a method to visualize biofilm production using 
a fluorescent transcriptional reporter (PtapA-yfp) for matrix gene expression.  The PtapA 
promoter regulates the tapA operon which encodes TasA, the major protein component of B. 
subtilis biofilms (24).   We can drive production of a yfp gene with PtapA so that when 
Bacillus subtilis is producing biofilm matrix, they are also producing YFP. Here, we use this 
reporter in coculture with other bacteria to identify signals that affect biofilm production.  
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Other members of the Bacillus genus have been shown to stimulate Bacillus subtilis 
to differentiate into matrix-producing cells (12).  Previous work has shown that members of 
genus Bacillus stimulate biofilm production through two mechanisms (12).  This includes 
signaling through sensor histidine kinase kinD (one of the kinases regulating phosphorylation 
of Spo0A), and a non-kinD dependent pathway that was potentially linked to the presence of 
specialized metabolites (12).  We identified the secreted, natural product thiocillin produced 
by Bacillus cereus ATCC 14579 as an inducer of B. subtilis biofilm formation through both 
mechanisms (12).  By using our fluorescent transcriptional reporter assay, coupled to matrix-
assisted laser desorption/ionization time-of-flight imaging mass spectrometry (MALDI-TOF 
IMS), the thiocillins were identified as the B. cereus compounds that stimulate biofilm 
formation in a kinD-independent mechanism.   
 The thiocillins are members of the thiopeptide class of ribosomally-synthesized and 
post-translationally modified peptides (RiPPs) (25).  The thiopeptides are macrocyclic 
antibiotic peptides characterized by thiazoles or thiazolines, which are formed from cyclized 
cysteine residues, and dehydrated residues, such as dehyroalanines and dehydrobutyrines 
(Figure 2.1) (25).  The macrocycle is closed through formation of a 6-membered, N-
containing heterocycle that is usually a pyridine or dehydropiperidine (25).  The rigid 
macrocyclic structure causes thiopeptides to be conformationally constrained, which 
promotes their antibiotic activity and makes them less susceptible to degradation by 
proteases.  The thiopeptides have antibiotic activity against both Gram-positive and Gram-
negative bacteria by inhibiting translation, either through blocking the interaction between 
the 23S rRNA and the protein L11 of the 50S ribosome (26, 27) or by inhibiting Elongation 
factor Tu (EF-Tu) (25).  The mechanism of action of the thiopeptides is dependent on the 
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architecture of the macrocycle.  26-member macrocycles (determined by counting the 
number of atoms in the shortest path around the ring), such as thiocillin, inhibit the ribosome 
at protein L11, while 29-member macrocycles, such as GE-37468, inhibit EF-Tu binding to 
amino acyl tRNA (25).   
 To examine the effect of thiopeptides on Bacillus subtilis biofilm formation, we 
tested thiocillin-producer Bacillus cereus, genetically modified B. cereus thiocillin variants 
and purified thiopeptide compounds.  We also examine structure-activity relationships of the 
thiocillins on its biofilm induction ability.  Using homology to the known biosynthetic 
pathway of the thiocillins (28), we further identify and test the activity of putative 
thiopeptides from other Bacillus species. 
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Figure 2.1. Members of the thiopepide class of RiPPs.  
 
2.2 Connecting phenotype to chemotype 
 We used the PtapA-yfp fluorescent transcriptional reporter strain of B. subtilis to 
monitor biofilm production in response to external signals.  We used this strain to examine a 
coculture of the B. subtilis reporter and the thiocillin-producer, B. cereus, under conditions in 
which B. subtilis would not normally produce matrix (Figure 2.2.A).  The B. subtilis 
microcolonies closest to the B. cereus colony fluoresced earlier than the colonies farther 
away, indicating that the tapA operon was being upregulated and biofilm production was 
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stimulated in those colonies (Figure 2.2.B) (12).  To confirm that this phenotype was caused 
by a specialized metabolite signal, we used MALDI-TOF IMS to connect the fluorescence 
with the mass of the compound responsible for its activation.     MALDI-TOF IMS allows us 
to correlate a particular ion mass with its spatial distribution by collecting mass spectra 
across a 2D space and looking for the localization of a particular mass (29, 30).  We found an 
ion with an m/z = 1142, identified in linear negative mode, that correlates to the spatial 
distribution of the biofilm induction phenotype (Figure 2.2.C).  This ion also corresponds to 
the mass of a variant of thiocillin, micrococcin P1 [M-H]-, suggesting that the thiocillins were 
involved in the biofilm formation signaling phenotype (Figure 2.2.C-D).  
 
Figure 2.2. Connecting thiocillin to matrix-production in B. subtilis.  A. Co-culture set-up 
with fluorescent biofilm reporter of B. subtilis grown in the presence of B. cereus colony. 
(Scale Bar = 0.5 cm). B. The transcriptional reporter is activated as the microcolonies closest 
to B. cereus fluoresce. C. IMS data showing the distribution of m/z = 1142 ion in linear 
negative mode. D. Structure of thiocillin variant, micrococcin P1. 
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2.3 Thiocillin validation and mechanism of action 
2.3.1 Thiocillin mechanism is kinD-independent 
 To further characterize the co-culture interaction between B. cereus and B. subtilis, 
we used a genetic mutant of B. cereus that did not have the structural genes required for 
thiocillin production ('tclE-H) (31).  We compared the mutant to the wild-type (WT) 
Bacillus cereus in our fluorescent reporter assay.  Additionally, we wanted to determine 
whether the kinD-dependent or independent mechanism was being activated by thiocillin.  It 
has been previously reported that B. cereus used two mechanisms to induce biofilm, one 
through sensor histidine kinase, KinD, and one that correlates with a specialized metabolite 
antibiotic signal (12).  To determine which mechanism, we used our same transcriptional 
reporter in a 'kinD strain of Bacillus subtilis.  We were able to then visualize and quantify 
the fluorescence for the combinations of B. subtilis and B. cereus (Figure 2.3.A).  Our 
quantification showed that thiocillin was directly responsible for about half of the biofilm 
induction activity of Bacillus cereus, as highlighted by the reduced fluorescence when the 
thiocillin structural genes are knocked-out (Figure 2.3.A).  Additionally, we determined that 
the other half of the activity was through a kinD-dependent mechanism that was thiocillin-
independent.  When the thiocillin-producing B. cereus colony interacted with the 'kinD B. 
subtilis reporter, we saw about half of the quantified fluorescence. When neither thiocillin 
nor KinD was present in the interaction, virtually all fluorescence was abolished (Figure 
2.3.A).  
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2.3.2 Thiocillin mechanism is independent of antibiotic activity  
We next wanted to determine if the thiocillin biofilm induction activity could be 
attributed to its antibiotic effect.  The thiocillins could be inducing fluorescence by 
selectively killing non-matrix-producing cells.  To test this hypothesis, we examined the 
activity of an engineered strain of B. cereus that produces a T4V mutant of thiocillin, which 
has been previously shown to be devoid of antibiotic activity against B. subtilis (31).  We 
cocultured this strain with both the WT and 'kinD B. subtilis fluorescent reporters and 
discovered that the T4V mutant induces biofilm production to the same extent as the WT 
thiocillin for both reporters (Figure 2.3.B).  Thus, the signaling of biofilm induction is 
independent of thiocillin’s antibiotic activity. 
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Figure 2.3. Thiocillin validation and mechanism of action. A. Thiocillin induces matrix-
production in B. subtilis in a kinD-independent manner (n=3). B. Thiocillin induces matrix-
production independent of antibiotic activity (n=3). *P < 0.1, **P < 0.05. 
 
 We examined colony morphology changes to further validate the fluorescence results.  
To this end, we examined the Bacillus subtilis microcolonies for morphological changes 
when grown next to the different strains of Bacillus cereus.  In this assay, wrinkling of the 
colonies corresponds to matrix production (32).  We set up the coculture under the same 
conditions as the fluorescent reporter assays using WT B. subtilis.  Compared to the 
microcolonies grown in the absence of B. cereus, the B. subtilis colonies grown in close 
proximity to B. cereus showed increased wrinkling and hence increased biofilm production 
(Figure 2.4).  The wrinkling present in the colonies next to the B. cereus 'tclE-H strain is a 
result of the kinD mechanism.  Additionally, the colonies grown next to WT and T4V B. 
cereus showed the greatest wrinkling, while the colonies next to T4V grew bigger and closer 
to B. cereus due to the lack of antibiotic effect (Figure 2.4). 
 
Figure 2.4. B. cereus causes biofilm morphological changes in B. subtilis colonies in 
coculture. (Scale bar = 0.5 mm) 
No colony ΔtclE-H B. cereusWT B. cereus T4V B. cereus
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 To further confirm the lack of correlation between antibiotic activity and biofilm 
induction, we used our fluorescent transcriptional reporter assay to test various laboratory 
antibiotics for their ability to induce biofilm in B. subtilis.  In the presence of 450 ng of 
antibiotic, we saw variability in the levels of biofilm formation, indicating this signaling 
event is not specific to antibiotics (Figure 2.5). Erythromycin and chloramphenicol both 
induced biofilm production, while kanamycin and tetracycline showed minimal induction 
(Figure 2.5).  Other antibiotics, such as ampicillin, spectinomycin, and holomycin, all 
showed no biofilm induction, although ampicillin is an especially strong antibiotic against B. 
subtilis (Figure 2.5). 
 
Figure 2.5. Antibiotic activity does not correlate to biofilm induction in B. subtilis (n=3). 
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2.4 Biofilm formation activity across thiopeptides 
In our initial results, we directly correlated induction of biofilm production in B. 
subtilis to the natural product, thiocillin.  We further hypothesized that this might be a more 
general property of thiopeptides.  To this end, we tested a small library of purified 
thiopeptides in the fluorescent transcriptional reporter assay for both WT and 'kinD B. 
subtilis microcolony lawns. Purified compounds were used for these experiments because 
many of the thiopeptides are produced by organisms with different growth rates, and using 
pure compounds would allow us to control of the amount of compound present. Using 
purified compounds also reduces background from other factors that might influence B. 
subtilis biofilm production.  We tested a broad range of structurally and functionally diverse 
thiopeptides that included different macrocycle sizes in both the WT and kinD B. subtilis 
lawns (Figure 2.1).  We spotted 450 ng of purified compound on the B. subtilis microcolony 
lawns and quantified the fluorescence.  We found no significant difference (P > 0.1) between 
the induction of the different thiopeptides across both the WT and kinD B. subtilis lawns 
(Figure 2.6).  Additionally, two of the thiopeptides, thiostrepton and berninamycin, both 
exerted antibiotic activity at this concentration.  This indicates that inducing biofilm 
formation is a more general activity of thiopeptides, and that thiopeptides activate gene 
expression in both a kinD-independent and antibiotic-independent fashion. 
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Figure 2.6. Purified thiopeptides induce biofilm formation in Bacillus subtilis (n=3-13). 
 
2.5 Structure activity relationship of thiocillin and biofilm induction 
Next, we wanted to probe the specificity of thiocillin’s biofilm induction activity.  To 
this end, we examined a variety of structural mutants of thiocillin produced by different 
engineered strains of B. cereus. We tested mutations that disrupted each individual thiazole 
ring in the macrocycle (C2A, C5A, C7A, and C9A), as well as ring expanded (A78) and 
linear ('tclM) versions (Figure 2.7) (33, 34). 
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Figure 2.7. Structures of thiocillin mutants used in SAR study. 
 
 Each engineered mutant thiocillin strain of B. cereus was spotted on microcolony 
lawns of both WT and kinD B. subtilis with the transcriptional reporter.  In each instance, we 
observed that mutants induced fluorescence to about half the level of WT B. cereus on the 
WT B. subtilis lawn, and had no effect on yfp expression on the kinD B. subtilis lawn (Figure 
2.8.A).  This data is similar to the activity observed for the 'tclE-H B. cereus mutant that 
was unable to produce any thiocillin, suggesting that none of these variants are able to induce 
biofilm-matrix expression in B. subtilis.  To confirm that these strains were expressing the 
thiocillin variants in the assay, we used MALDI-TOF IMS to detect production of thiocillins 
in vivo.  We grew the various B. cereus strains in the same manner we would for the 
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fluorescence assay but without the microcolony lawns, and looked for the presence of masses 
for each variant.  For each mutant strain, we found at least one compound corresponding to 
an expected mass, indicating that major structural alterations abolish the ability of thiocillin 
to induce biofilm gene expression (Figure 2.8.B).  Even though modifications, such as T4V, 
which abolish antibiotic activity were well tolerated, other modifications to the core thiocillin 
structure do affect its ability to induce biofilm production.  Further testing of specific purified 
thiocillin variants showed that minor structural differences (Figure 2.7) can lead to 
differences in biofilm induction activity (Figure 2.9). B. cereus natively produces several 
difference thiocillin variants, but it is still unknown whether they act in a synergistic or 
additive manner (Figure 2.7). 
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Figure 2.8. Structural modifications to thiocillin abolish biofilm induction activity. A. 
Quantification of fluorescence intensity of B. subtilis WT or kinD PtapA-yfp microcolonies 
when cocultured with thiocillin mutant producers (n=3).  B. Images of B. cereus mutant 
thiocillin colonies grown on agar on MALDI plate with corresponding IMS data.  Colors 
represent ions of indicated m/z: WT [M+H+Na]+; A78 [M+H+Na]+; C2S [M+Na+K]+; C5A 
[M+H]+; C7A [M+H+Na]+; C9A [M+H+Na+K]+; ΔtclM [M+H]+.  
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Figure 2.9.  Natural thiocillin variants have different levels of biofilm induction activity 
(n=3).  
 
2.6 Cryptic thiopeptides induce biofilm formation 
 Other Bacillus species also are able to promote matrix gene expression in B. subtilis 
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so it was impossible to determine if they also possess thiopeptide biosynthesis genes.  To test 
if other Bacillus strains that had the biosynthetic machinery for thiopeptide production could 
also induce biofilm formation in B. subtilis, we first had to identify strains that contained 
these pathways.  We used the lantibiotic dehydratase thiopeptide biosynthesis genes (shown 
in orange in Figure 2.10) in homology models to look through all available Bacillus 
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putative thiopeptide biosynthetic pathways that also contained other key thiopeptide 
biosynthetic genes (36, 37).  This includes the cyclodehydratase that catalyzes thiazole 
formation, structural genes, transporters, and other biosynthetic machinery (Figure 2.10).  
We had access to two of these strains, and tested them for their ability to induce fluorescence 
in our transcriptional reporter assay with both WT and kinD B. subtilis (Figure 2.10 and 
Figure 2.11). Both of the strains tested, Bacillus atrophaeus 1942 and Bacillus sp. 107, 
induced biofilm gene expression similar to B. cereus with the WT B. subtilis microcolony 
lawn (Figure 2.10). Only Bacillus atrophaeus induces biofilm formation in a kinD-
independent manner (Figure 2.10).  The putative thiopeptide biosynthetic pathway from 
Bacillus sp. 107 does not appear to contain a dehydrogenase, which is needed to form the 
final thiazole from a thiazoline generated by the cyclodehydratase, and it is possible that it 
does not form a typical thiopeptide (Figure 2.10).  
 
 
Figure 2.10. Bacillus strains containing cryptic thiopeptide biosynthetic pathways induce 
biofilm gene expression in Bacillus subtilis. A. Biosynthetic pathways comparing the enzyme 
and structural gene sequences of cryptic thiopeptides from Bacillus atrophaeus and Bacillus 
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sp. 107 to the thiocillin pathway.  B. Quantification of fluorescence intensity of yfp induced 
by B. atrophaeus and B. sp. 107 with WT and kinD B. subtilis microcolony lawns (n=3). 
 
 
Figure 2.11. Bacillus strains containing cryptic thiopeptide biosynthetic pathways induce 
biofilm gene expression in Bacillus subtilis. 
 
2.7 Building substrates for pull-down assays  
2.7.1 Strategy for thiocillin probe 
In order to further probe the mechanism of biofilm induction by thiopeptides, we 
designed substrates that could be used to pull-down protein binding partners from B. subtilis 
lysate.  We designed derivatives of thiocillin had photo-activated reactive groups to facilitate 
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covalent binding to proteins and biotin handles to pull-down the thiocillin binding partner 
using streptavidin beads.  We chose a photo-activated diazirine group that would covalently 
bind to the protein upon addition of 365 nm light after incubation in lysate.  We designed our 
thiocillin probe to have the T4V mutation to minimize background binding to the ribosome 
and favor the biofilm induction activity.  We utilized a chemoenzymatic synthesis route to 
the thiocillin probe that was developed in the lab (38) where we could easily incorporate a 
terminal alkyne at various positions in thiocillin. This allows us to then use the biorthogonal 
copper-catalyzed azide-alkyne cycloaddition (CuAAC) click reaction to attach our 
biotin/photo-activiated handle that contained an azide (39, 40). 
 
2.7.2 Synthesis of photo-activated crosslinker 
 The design of the synthetic route to the photo-activated biotin handle followed the 
same route as that described by Luo, et al. (41). Basically, a two-step coupling procedure was 
utilized to assemble a diazirine photo-activated group, a biotin handle, and an azide with 
polyethylene glycol (PEG) linkers (Scheme 2.1). Each step was assessed by liquid-
chromotography mass spectrometry (LCMS). (See 2.9.11 Synthesis of photo-crosslinker 
and Appendix A). 
 
Scheme 2.1. Synthesis of photo-crosslinker.   
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2.7.3 Solid phase peptide synthesis of alkyne-containing thiocillins  
We utilized a chemoenzymatic approach that had been previously developed (38) to 
build thiocillin analogs that contained the T4V mutation and a terminal alkyne for futher 
biorthogonal chemistry.  To build the linear thiocillin core with its minimal leader peptide 
sequence for cyclization by the enzyme TclM (38), we did standard SPPS couplings using 
Fmoc protecting group chemistry (See 2.9.12 Solid Phase Peptide Synthesis).  The SPPS 
utilizes thiazole amino acid building blocks (38), and a propargyl glycine building block to 
install the terminal alkyne at either the T3 or T13 position of thiocillin (Figure 2.12). 
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Figure 2.12. Alkyne-containing thiocillin analogs synthesized using SPPS. 
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this process was to eliminate the cysteine residues in the core peptide that are part of the final 
pyridine ring to dehydroalanines.  This was done by adapting a previously reported procedure 
(42) (Scheme 2.2).  Secondly, the peptides are cyclized with the enzyme TclM from the 
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thiocillin biosynthetic pathway to complete the macrocycle through pyridine ring formation 
at the dehydroalanines (Scheme 2.3).  This results in the mature thiocillin analog that is 
ready for further biorthogonal chemistry (38). 
 
2.7.5 CuAAC click reaction to attach photo-crosslinker  
Once the alkyne-containing thiocillins were finished, we could then use the 
biorthogonal copper-catalyzed azide-alkyne cycloaddition (CuAAC) click reaction to attach 
our photo-crosslinking probe (39, 40).  We used reaction conditions similar to those that were 
previously reported (41), however we used CuI as a copper (I) source instead reducing a 
copper (II) source in the reaction (Scheme 2.4). We used TBTA as our coordinating ligand to 
further improve the rate of the reaction.  The reaction went to completion overnight, and we 
could then HPLC purify to obtain our final probe for the pull-down assays.   
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Scheme 2.2. CuAAC click reaction for final thiocillin probe. 
 
2.7.6 Thiocillin probes are still active in biofilm induction assay 
 The photo-crosslinking probes were assessed in the PtapA reporter assay to confirm 
that the newly installed group did not interfere with activity.  We tested this using our 
fluorescent transcriptional reporter assay using the PtapA-yfp kinD Bacillus subtilis 
microcolony lawn and spotting 450 ng of purified compound (Figure 2.13).  Both the T3 and 
T13 alkyne thiocillin probes with and without the photo-crosslinking handle still induced 
biofilm gene expression in a kinD-independent manner (Figure 2.13). The dark colonies 
indicate production of YFP via fluorescence (Figure 2.13). Additionally, there is no zone of 
inhibition for these compounds since we used the T4V mutant (Figure 2.13).  The thiocillin 
probes are ready for pull-down assays. 
 
Figure 2.13. Thiocillin probes are still able to induce biofilm gene expression in kinD B. 
subtilis (n=2). 
 
2.8 Summary 
 Natural product antibiotics can act as signaling molecules for communication 
between bacteria that alter gene expression and development.  We used a combination of 
T3Alkyne T3Alkyne + Probe T13Alkyne T13Alkyne + Probe 
 39 
coculture, fluorescent transcriptional reporter assays, and MALDI-TOF IMS to identify and 
characterize the thiocillins and thiopeptides family as chemical signals that induce biofilm 
formation in Bacillus subtilis.  We further show, using a combination of genetically 
engineered strains, that this occurs independently of the thiocillin’s antibiotic activity in a 
kinD-independent fashion.  We observe a complete loss of activity when major structural 
modifications are made to the thiocillin scaffolds, such as thiazole knock-outs, macrocycle 
ring expansion, and loss of macrocycle formation. This indicates that while biofilm induction 
is more general to diverse thiopeptides, key components of these scaffolds are necessary to 
induce gene expression. Additionally, we use bioinformatics tools to identity putative 
thiopeptide biosynthetic pathways in other species of Bacillus. We tested two of them 
(Bacillus atrophaeus 1942 and Bacillus sp. 107) for their ability to induce biofilm formation. 
Both strains induced biofilm gene expression, but only Bacillus atrophaeus did so in a kinD-
independent manner. 
 Future steps to further understand the mechanism thiocillin uses to induce biofilm 
formation in B. subtilis involve pull-down assays to determine thiocillin’s binding partner.  
We took a chemoenzymatic approach to synthesize thiocillin probes for this assay. This 
included SPPS on a linear version of thiocillin with the T4V mutation that had propargyl 
glycine inserted at the T3 or T13 position. We utilized the biorthogonal CuAAC reaction to 
attach a photo-crosslinking probe.  Once the final probe was complete, we confirmed it was 
still able to induce biofilm formation in Bacillus subtilis, and it is ready for use in pull-down 
assays.  
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2.9 Experimental 
2.9.1 General Methods 
 Solvents, reagents, and chemicals were purchased through Fisher Scientific and used 
as received unless otherwise noted. Amino acids, 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HATU), and O-(1H-6-Chlorobenzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) were purchased from ChemPep. 
N,N-diisopropylethyl amine (DIPEA) was purchased from Fisher Scientific. Preparatory 
HPLC was performed in a Shimadzu UFLC CBM-20A with a dual channel wavelength 
detector at 220 nm and 254 nm or 254 nm and 350 nm with a LUNA 10µ C18(2) 100 Å, 
AXIA (Phenomenex) semi-preparatory column with a 15 mL/min flow rate. Purifications 
were carried out with a two-solvent system (solvent A = 0.1% trifluoroacetic acid in water; 
solvent B = 0.1% trifluoroacetic acid in acetonitrile) using the following method unless 
otherwise noted. 
Time % Solvent B 
0 -2 min 5% 
2- 7 min 5 - 40% 
7 – 21 min 40-60% 
21- 23 min 55 – 100% 
23 – 28 min 100% 
28 – 30 min 100 – 5% 
30 – 32 min 5% 
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2.9.2 Culture Conditions 
All bioassay plates contained 20 mL, poured using a Wheaton Unispense liquid 
dispenser, of 0.1× LB (BD Difco), 100 mM MOPS, pH 7 (Sigma), and 1.5% (wt/vol) agar. 
Liquid LB broth contained no agar. All IMS plates contained 10 mL of 0.1× LB, poured by 
hand.  
2.9.3 Strains 
The strains used in this study are listed in Table 2.1. 
 
Table 2.1. Strains used in this study.  
2.9.4 Reporter Preparation 
B. subtilis reporter strains were prepared as described in (12). They were cultured in 
LB broth to midlog, diluted to an OD600 of 0.02, and regrown to midlog at least twice more 
to reduce background fluorescence. At midlog after these final dilutions, glycerol was added 
[15–20% (vol/vol) final], and aliquots were frozen at −80 °C. Before use, the cfu/mL of the 
aliquots was determined by plating serial dilutions on LB agar plates.  
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2.9.5 Matrix Induction Assay 
Reporter aliquots were thawed and diluted in LB broth to a concentration of 5 × 105 
cfu/mL, and 50 μL of this dilution was spread on 20 mL of 0.1× LB, 100 mM MOPS plates 
using 3-mm sterile glass beads. The organisms to be tested were resuspended in 1× LB broth 
to an OD600 of 0.5, and 3 μL of the cell suspension was spotted onto a dried plate freshly 
inoculated with a B. subtilis reporter microcolony lawn. Plates were grown at 24 °C. After 
24–26 h of growth, plates were scanned for fluorescence by using a Typhoon fluorescence 
imager (488 nm excitation, 526 nm emission, 500 PMT, 100-μm resolution, 3-mm scan 
height). 
2.9.6 Fluorescence Quantification 
Typhoon data files (.gel) were loaded into Metamorph (Version 7.1), and brightness 
and contrast were linearly adjusted. Quantification was performed essentially as described in 
(12), except that thresholding was not used. In brief, four concentric regions of interest were 
defined around each colony spot, with the difference between the outer two representing the 
background fluorescence of the plate, and the difference between the inner two representing 
the fluorescence intensity in the area of matrix-induction. After background subtraction, the 
average integrated intensity per area values were normalized by the background values to 
account for interplate variability. Values from each replicate assay were scaled relative to the 
maximum measured intensity for WT B. cereus for that assay to reduce noise and allow 
comparisons between biological replicates. Values for at least three independent experiments 
were averaged. Error bars are the SD.  
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2.9.7 MALDI-TOF IMS 
IMS was performed as described in (30). Pieces of 10-mL 0.1× LB agar plates on 
which either B. subtilis lawns spotted with B. cereus or colonies of the B. cereus thiocillin 
mutants had been grown were excised from the plate and placed onto Bruker MSP 96 target 
ground steel target plates (Bruker part no. 224990) and covered with Universal MALDI 
matrix (Sigma, Fluka 50149) using a 53-μm stainless steel sieve (Hogentogler & Co, part 
1312). The sample was dried onto the target plate overnight at 37 °C. Excess matrix was 
removed, and a peptide calibration standard was spotted onto the plate (Bruker part no. 
206195, Pepmix4). IMS data were collected across the samples by using a Bruker Microflex 
LRF MALDI-TOF mass spectrometer and FlexControl and FlexImaging software. Data were 
collected in both linear-positive and linear-negative mode for both samples, with 80 shots 
averaged from each pixel of 400–800 μm across an m/z of 0–5,000 Da. The data were then 
examined manually in 0.5-Da increments for mass signals of interest, which were false- 
colored for display.  
2.9.8 LCMS  
LCMS data were acquired on an Agilent 6520 Accurate-Mass Q-TOF mass 
spectrometer with an electrospray-ionization source in positive ion mode. The drying gas 
temperature was 350 °C, and the fragmentor voltage was 250 V. The thiazolyl peptides were 
separated by using a reverse-phase kinetex column; acetonitrile with 0.1% formic acid was 
run as a gradient from 2% to 100% over 15 min and held at 100% for 2 min against water 
with 0.1% formic acid.  
2.9.9 Thiocillin purification and concentrations 
Thiocillin, its mutants, and other thiazolyl peptides were all purified as reported in 
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(31). Purified thiazolyl peptides were maintained as stocks at a concentration of 250 ng/μL in 
DMSO. For matrix induction assays, 1.8 μL (containing 450 ng) was spotted onto a dried 
plate freshly inoculated with a B. subtilis reporter microcolony lawn.  
2.9.10 Statistics 
All P values were calculated with a Tukey’s honest significant difference pairwise 
analysis using JMP software.  
2.9.11 Synthesis of photo-crosslinker 
L-Photo-Methionine (10.9 mg, 0.0692 mmol, 1.0 equiv.) from ThermoFisher was 
dissolved in 600 PL of a 1:1 mixture of DMF-DMSO in a 1.5 mL Eppendorf tube covered by 
aluminum foil. Briefly sonicate, and add DIPEA (52 PL, 0.28 mmol, 4.6 equiv.). Then add 
Biotin-PEG4-NHS (43.6 mg, 0.084 mmol, 1.3 equiv.) purchased from ConjuProbe before 
placing the mixture at 55 oC for 14 hours. An aliquot of the reaction mixture was analyzed by 
LCMS to confirm the reaction had gone to completion (C27H46N6O9S, calculated exact mass: 
631.31, experimental exact mass: 631.3100). 
The mixture was cooled to 4 oC before adding HATU (31.8 mg, 0.0692 mmol, 1.0 
equiv.) dissolved in 120 PL of DMF.  Additional DIPEA was added (14 PL, 0.0692, 1.0 
equiv.), and the mixture was brought to room temperature and left for 5 minutes.  The 
mixture was then treated with Azido-PEG3-NH2 (28 mg, 0.126 mmol, 2.0 equiv) purchased 
form ConjuProbe in a 50 PL DMF solution. The mixture was placed at 37 oC for 14 hours. 
An aliquot of the reaction mixture was analyzed by LCMS to confirm the reaction had gone 
to completion. The compound was directly purified using reverse phase HPLC on a 
Shimadzu UFLC CBM-20A monitored at 350 nm with a LUNA 10µ C18(2) 100 Å, AXIA 
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(Phenomenex) semi-preparatory column with a 15 mL/min flow rate. Purification was carried 
out with a two-solvent system (solvent A = 0.1% trifluoroacetic acid in water; solvent B = 
0.1% trifluoroacetic acid in acetonitrile) using the method detailed below. Fractions were 
pooled and lyophilized to obtain the product. (C35H62N10O11S, calculated exact mass: 831.44, 
experimental exact mass: 831.4401). 
Method: 
Time % Solvent B 
0 -2 min 5% 
2- 5 min 5 - 25% 
5 – 18 min 25-55% 
18- 22 min 55 – 100% 
22 – 24 min 100% 
24 – 26 min 100 – 5% 
26 – 28 min 5% 
 
2.9.12 Solid Phase Peptide Synthesis 
Chem-Matrix Resin (10 mg, 0.47 mmol peptide/g resin) is initially swollen in DMF 
(2.0 mL) for 1.5 hours at room temperature, shaking on the mini-block. 
(i) Coupling: Fmoc-AA-OH (5.0 equiv., for final 1 mL volume in DMF), HCTU (5.0 
equiv., 0.5 M in DMF), and DIPEA (10.0 equiv., 1.0 M in DMF) were added to the swollen 
resin in that order. The resulting suspension was shaken on the mini-block at room 
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temperature for 15 min. The reaction vessel is then drained and resin is thoroughly washed 
with DCM four times. 
(ii) Fmoc removal: Following coupling, 2.0 mL of 20% piperidine in DMF is added 
to the reaction vessel and allowed to incubate for 10 min while shaking at rt. The reaction 
vessel is drained, washed with DCM four times.  
(iii.) Cleaving off the resin: Once peptide is complete, resin is resuspended in 95% 
TFA with 2.5% water and 2.5% TIPS and allowed to shake for 2 hrs at 37 oC.  The resin is 
filtered through a cotton plug, and the flow through is concentrated to less than 1 mL volume.  
A 10-fold excess of diethyl ether (Et2O) is added to crash out the peptide from the solution.  
The peptide is centrifuged, decanted, and resuspended in DMSO before purification and 
lyophilization or LCMS analysis. 
 
2.9.13 Elimination of Cysteines to Dehydroalanines 
 
  
Scheme 2.3. Elimination of cysteines to dehydroalanines. 
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Adapted from previously described method (42).  Briefly, in a 1.7 mL 
microcentrifuge tube, cysteine-containing substrate is dissolved to a final concentration of 
633 PM in a solution containing 50% (aq.) DMF and 1.26 mM TCEP. Mixture is allowed to 
incubate for 30 min at 37 oC, after which 2,5-dibromovalerate and K2CO3 are both added to a 
final concentration of 63 mM. Reaction is allowed to shake at 37 oC for 3 h. Excess 2,5-
dibromovalerate is removed by washing with Et2O three times: Et2O (500 PL / 50 PL 
reaction) is added, vortexed for 3 s, and centrifuged for 10 s at 6,000 rpm. Carefully, top 
ether layer is removed. Microcentrifuge tube is set at 37 oC with the cap open to remove 
excess Et2O for 10 min. Substrates were utilized without further purification. 
 
2.9.14 Cyclization by TclM 
 
 Scheme 2.4. Cyclization by TclM to alkyne-containing thiocillin. 
 
Cyclization was performed in a 50 mM HEPES (pH = 7.9) and 150 mM NaCl buffer 
with final concentrations of 20 PM substrate and 10 PM of TclM in 50 mL reaction volumes. 
Reactions were incubated at 25 oC and 80 rpm for 20 h, after which 100 mL of methanol 
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were added, incubated at rt for 3 min, and precipitated protein removed by centrifugation (5 
min at 4,000 rpm) and the supernatant collected. The supernatants were analyzed by LCMS 
and concentrated to remove methanol.  Additionally, the remaining peptide was desalted 
using a C18 Sep Pak Cartridge from Waters Corporation and eluting in 5 mL of methanol 
and concentrating again.  Peptides were used without further purification. 
2.9.15 CuAAC Click Reaction 
The CuAAC reaction procedure was adapted from (41). The cyclized alkyne-
containing thiocillins (1 mg, 1.0 equiv.) were dissolved in 3.2 mL of DMSO and buffered 
with 100 mM HEPES upon addition of 400 PL of 1M HEPES-KOH pH 7.0.  Then photo-
crosslinker (1mg, 2.0 equiv.) in 200 PL of DMSO is added, followed by 100 PL of a 1:1 
mixture of TBTA:CuI at 50 mM each in DMSO and 100 PL of a 100 mM sodium ascorbate 
solution in water.  The reaction is placed at 37 oC for 16 hours and checked for completion 
by LCMS.  The probe is purified using reverse phase HPLC as described in 2.9.1 General 
Methods. T3alkyne thiocillin probe (C81H108N23O17S7, calculated exact mass: 1884.6177, 
experimental exact mass: 1883.6344). T13alkyne thiocillin probe (C82H107N23O17S7, 
calculated exact mass: 1914.6282, experimental exact mass: 1914.6134). 
2.9.16 TclM Expression and Purification 
TclM protein was heterologously expressed in E. coli RIPL cells as an MBP fusion 
protein and purified as previously reported (38). 1 L of Luria-Bertani (LB) medium, 
supplemented with ampicillin (100 Pg/mL) and chloramphenicol (34 Pg/mL), was inoculated 
with 5 mL of an overnight culture and grown to an OD600 between 0.6-0.8 at 37 oC, at which 
point 200 PL of a 1 M stock of IPTG was added.  The culture was grown for 18 h at 16 oC. 
Cells were pelleted and resuspended in 40 mL of lysis/binding buffer (50 mM KHPO4 at pH 
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= 7.00, 250 mM KCl, 10 mM imidazole, and 10% glycerol) supplemented with 250 Pg/mL 
lysozyme, and 2 mM PMSF. Cells were lysed by sonicating twice with a 30% maximum 
amplitude intermittent pulses for 1:30 min. Cell debris was removed by centrifugation (20 
min at 16,000 rpm at 4 oC) and supernatant collected and cold filtered through a 0.44 Pm 
filter. Supernatant was loaded into a 5-mL HisTrap (Ni2+) IMAC column and washed (4 CV) 
to remove non-specific binding. 6xHis-MBP-TclM was eluted with an elution buffer gradient 
(50 mM KHPO4 at pH = 7.00, 250 mM KCl, 500 mM imidazole, and 10% glycerol) from 0 – 
100% (5 CV). Fractions containing eluted protein are pooled and concentrated to 5 mL 
utilizing a Centricon (30,000 Da MWCO) concentrator (EMD Millipore®). The resulting 
concentrated protein was buffer-exchanged into 50 mM KHPO4 at pH = 7.00, 250 mM KCl, 
and 10% glycerol utilizing a PD-10 column (GE Healthcare Life Sciences®) to obtain 3.5 mL 
of 6xHis-MBP-TclM.  
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CHAPTER III 
LARGE SCALE BIOINFORMATIC ANALYSIS OF BACILLUS GENOMES 
UNCOVERS CONSERVED ROLES OF NATURAL PRODUCTS IN BACTERIAL 
PHYSIOLOGY 
3.1 Introduction 
  Bacteria devote large portions of their genomes to produce a wide array of natural 
products or secondary metabolites. These specialized metabolites have been crucial to the 
development of antibiotics. More recently, they have garnered attention as intraspecies and 
interspecies signals that affect bacterial physiology and development (1–5). Due to the 
important roles that bacterial specialized metabolites play, there is interest in identifying the 
entire repertoire of metabolites that bacteria are capable of generating and identifying their 
biological functions. Previous work has shown that within one genus, Bacillus, many 
interactions and communication occur predominantly with closely related species (6).   
Most specialized metabolites are structurally complex biomolecules that fall into 
distinct structural classes synthesized by conserved groups of biosynthetic enzymes. This 
association between metabolites and their gene signature allows genome sequences to be 
mined to identify predicted biosynthetic gene clusters (BGCs). Genome mining has rapidly 
expanded our knowledge of the number of specialized metabolites that bacteria are capable 
of producing, and has dramatically increased the rate of discovery of specialized metabolites 
compared to traditional methods, which rely on the isolation of individual compounds (7, 8). 
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Several large-scale genome-mining projects have focused on defining the specialized 
metabolite potential of actinobacteria, a bacterial group known to be prolific producers of 
natural products and the taxon that has supplied the majority of clinically deployed 
antibiotics (9). In contrast, we focused our efforts on Gram-positive Bacilli, an underexplored 
genus that possesses substantial biosynthetic potential.  
We focus on Bacilli, in part, because they exhibit diverse biological behaviors in their 
native context. Bacillus species are omnipresent in soils and in the plant rhizosphere, and 
many have been harnessed and heavily exploited for industrial and agricultural applications. 
Some species are considered safe biological agents and are used as plant-growth-promoting 
bacteria or food additives, while others are pathogens (10, 11). Additionally, the specialized 
metabolites of Bacilli play significant roles in the interactions and life cycles of these bacteria 
as both intra- and interspecies signals. Many Bacillus specialized metabolites coordinate 
cellular differentiation (12, 13). For example, the non-ribosomally produced lipopeptide 
surfactin is important for development of multicellularity in Bacillus subtilis, acting as a 
quorum-sensing-like signal that stimulates biofilm production (14, 15). Surfactin also acts as 
an interspecies signal, inhibiting aerial hyphae formation in Streptomyces coelicolor (16), 
and as an antibiotic (it is one of more than two-dozen antibiotics that have been isolated from 
strains of B. subtilis). Bacillaene, a hybrid non-ribosomal peptide and polyketide, is also 
involved in interspecies interactions. It inhibits prodiginine production in Streptomyces 
species (17) and protects B. subtilis against predation by Myxococcus xanthus (18). More 
recently, a group of ribosomally synthesized and post-translationally modified peptides 
(RiPPs) produced by B. cereus, known as thiocillins, have been shown to stimulate B. subtilis 
to produce biofilm in a manner that is independent of antibiotic activity (6, 19). Thus, 
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specialized metabolites are an important means by which Bacilli interact with themselves and 
their surroundings.  
To more broadly examine the metabolic repertoire of Bacilli, we deploy intensive 
bioinformatics to survey the breadth and diversity of chemical ecology encoded within 
Bacillus genomes.  Although previous efforts have sought to assess the metabolic diversity of 
this genus (20), our analysis uses new and significantly larger datasets to measure the 
conservation of BGCs across Bacilli and to further distinguish secondary metabolites 
involved in their lifecycles and social interactions.  Our analysis highlights that metabolites 
with highly-conserved biosynthetic genes are likely to play important roles in regulating 
Bacillus physiology and development.  As evidence of this trend, we isolate a highly 
conserved group of alkylpyrones and elucidate their role as chemical signals that regulate 
sporulation in B. subtilis. Additionally, a large number of Bacilli possess unique BGCs that 
encode unknown metabolites, which have been acquired predominantly through horizontal 
transfer.  This analysis provides insights into the chemical ecology of Bacilli and a strong 
foundation for future assessment of their biosynthetic capabilities.  
 
3.2 Dataset 
 A distinctive feature of this analysis is the large number of sequences from a single 
genus that were examined. We analyzed the 221 Bacillus genomes that were publicly 
available at the time that we began this work, as well as 1,345 proprietary Bacillus genomes 
from AgBiome (Figure 3.1). By comparison, we have evaluated almost five times more 
genomes than the next-most-extensive published analyses (20), and significantly more than 
other similar analyses of other bacterial genera (9).  
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 In order to designate species names, we used Barrnap to identify 16S and 23S 
ribosomal gene sequences in each genome and used the predicted sequences in a BLAST 
search against the Genomic Reference Sequence Database (GenomicRefSeq). To streamline 
the presentation of results, we assembled the Bacilli in into groups containing 
phylogenetically related species: the cereus, subtilis, flexus, coagulans, and ‘other’ groups 
(Figure 3.5).   
 
Figure 3.1. Dataset for all Bacillus genomes with the number of strains in each species 
indicated on the right side of the phylogenetic tree.  Colors correspond to a particular species.   
 
3.3 Bioinformatics workflow 
 To evaluate the biosynthetic potential of these Bacilli, we developed an analysis 
pipeline (Figure 3.2). Our workflow integrates several bioinformatics tools to effectively 
analyze and visualize the biosynthetic potential of Bacilli and draw meaningful comparisons.  
We began by using antiSMASH (21) to analyze the biosynthetic capabilities of our 1,566 
genomes. The cumulative output from antiSMASH was 19,962 biosynthetic gene clusters 
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(BGCs), which included non-ribosomal peptide synthetases (NRPS), polyketide synthases 
(PKS), bacteriocins, thiopeptides, lanthipeptides, terpenes, ectoines, phosphonates, 
siderophores, and hybrid/non-traditional BGCs. Representatives of 23 characterized Bacillus 
BGCs (Table 3.1) were combined with these predicted BGCs for a 19,985 member 
MultiGeneBlast (MGB) library. These BGCs were analyzed using MultiGeneBlast (22), a 
program that does an all-by-all comparison and calculates a MultiGeneBlast score (MGB 
score) for each BGC pair based on their synteny and BLAST scores. MGB scores were 
normalized and used as input for DBScan (23) to cluster similar BGCs. Parameters selected 
for DBScan clustering (Table 3.2) were conservative, so that only highly related BGCs were 
placed in the same DBScan cluster. In some cases, this led to multiple DBScan clusters being 
generated for related molecular families. This level of stringency should result in only 
significant relationships being exposed.  Using the averaged MGB scores, we generated a 
distance matrix to describe the relatedness of each DBScan cluster to all other DBScan 
clusters in our MGB database. We sorted the resulting DBScan clusters by the class of 
natural product they contained (e.g. NRPS, PKS, etc.) based on antiSMASH assignments. 
We then used CytoScape (24) to build network maps that allowed the relationships between 
the DBScan clusters to be visualized.  These network maps provide an overview of the 
grouping of specialized metabolites within the Bacilli. By mapping the characterized, known 
BGCs onto the network maps, the vast unknown diversity of Bacillus specialized metabolites 
was revealed. The quality of the DBScan clustering was confirmed through a silhouette 
coefficient calculation (25) for each network map (Table 3.2). 
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Figure 3.2. Workflow for bioinformatics calculations. 
 
 Additionally, we used AlienHunter (26) to predict DNA regions that are likely to be 
obtained via horizontal gene transfer (HGT). We overlaid these results with those obtained 
from antiSMASH to determine how much of each BGC was obtained via HGT. AntiSMASH 
is highly conservative in defining the boundaries of BGCs to avoid excluding 
uncharacterized tailoring enzymes, which frequently leads to non-biosynthetic regions of the 
genome being included in antiSMASH’s output of BGCs. Because of this, we used a cutoff 
of 75 % overlap for designating BGCs as predicted to be obtained via HGT. 
Identify highly conserved BGCs and unique singletons
Map ‘known’ natural product clusters onto network map
Visualize the DBScan cluster relationships using network maps 
Create averaged distance matrix between DBScan clusters
Use DBScan to cluster similar BGCs
Use MultiGeneBlast scores to generate a distance matrix for BGCs
Run an “All vs. All” MultiGeneBlast analysis of BGC Database
Obtain list of ‘known’ Bacillus natural product BGCs from literature
Combine the cumulative output into an BGC Database
Analyze Bacillus genomes using antiSMASH
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Table 3.1. Bacillus compounds with known BGCs. 
 
 
Table 3.2. Overview of Bacillus species and BGC diversity and DBScan optimized 
parameters with silhouette coefficient scores. 
 
3.4 Validating the bioinformatics workflow 
To verify our bioinformatics methods, we examined a subset of bacterial strains 
predicted to produce known metabolites. For structures of known Bacillus metabolites, see 
Figure 3.3. We used high-resolution LCMS to survey the cell-surface extracts of strains 
Number Compound Structure 
Class 
Sequenced Producer 
1 Bacillibactin nrps B. subtilis 168 
2 Surfactin nrps B. amyloliquefaciens FZB42, B. subtilis 
3 Bacilysin other B. subtilis A1/3, B. amyloliquefaciens FZB42, B. pumilus 
4 Bacillaene nrps-t1pks B. amyloliquefaciens FZB42  
5 Subtilosin A bacteriocin B. subtilis ATCC 6633 
6 Difficidin transatpks B. amyloliquefaciens FZB42  
7 Haloduracin lantipeptide B. halodurans C-125 
8 Mersacidin  lantipeptide Bacillus sp. HIL-Y85/54728 
9 Ericin  lantipeptide B. subtilis A1/3 
10 Subtilin  lantipeptide B. subtilis ATCC 6633 
11 Sublancin  lantipeptide B. subtilis 168 
12 Cerein bacteriocin B. cereus 
13 Megacin  bacteriocin B. megaterium 216 
14 Cereulide nrps B. cereus 
15 Lichenysin nrps B. licheniformis ATCC 10716 
16 Fengycin nrps B. subtilis, B. amyloliquefaciens FZB42 
17 Zwittermicin nrps-t1pks B. thuringiensis YBT-1520, B. cereus UW85, B. cereus AH1134 
18 Mycosubtilin nrps-transatpks B. subtilis ATCC 6633 
19 Iturin nrps-transatpks B. subtilis RB14, Bacillus sp. CY22, B. subtilis MH25, B. amyloliquefaciens 
20 Bacillomycin D nrps-transatpks B. subtilis, B. amyloliquefaciens 
21 Plantazolicin other B. amyloliquefaciens FZB42  
22 Rhizocticin phosphonate B. subtilis ATCC 6633 
23 Macrolactin transatpks B. amyloliquefaciens FZB42  
 
Table S1
cereus subtilis other
   
   
  
3 (29%)
0 (100%)
0 (31%)
1 (100%)
0 (99%)
24%
63%
68%
52%
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2 (75%)
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2%
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0%
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1 (100%)
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predicted to produce kurstakins (two public and 36 AgBiome strains) and those predicted to 
produce bacillamide (three public and 16 AgBiome strains). We found masses corresponding 
to kurstakin and bacillamide production in 79 % and 58 % of the strains predicted to produce 
these metabolites, respectively (Figure 3.4). We speculate that other strains predicted but not 
detected to make these compounds may contain ‘silent’ BGCs where the metabolites are not 
expressed in laboratory growth conditions (27). This analysis confirms the effectiveness of 
our bioinformatics predictions and underscores the prevalence of these compounds in 
Bacillus strains. 
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Figure 3.3. Structures of known Bacillus metabolites. 
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Figure 3.4. LCMS distributions of kurstakins and bacillamides in predicted strains.  Area 
under EIC is the value given when integrating the area under the extracted ion chromatogram 
for each mass of the various kurstakins and bacillamides. 
 
3.5 General results and trends 
Overall, the Bacilli are relatively homogeneous in their metabolite distributions, 
especially within each phylogenetic group.  For instance, species from the cereus and subtilis 
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groups have large numbers of NRPS and bacteriocins, while the flexus and ‘Other’ groups 
are highly enriched in terpenes (Figure 3.5.A). Bacilli average 11 BGCs per strain, but this 
number can vary between 1-16 depending on the strain (Figure 3.5.A).  Although a large 
proportion of the strains are in the cereus group, this afforded the chance to more deeply 
sample this important portion of the Bacillus taxon and gain further insight into metabolite 
conservation among one bacterial species. The distribution of known and unknown BGCs 
varies across the different specialized metabolite classes (Figure 3.5.B). NRPSs are the most 
abundant class of specialized metabolite within our dataset, comprising 5081 BGC 
representatives (Figure 3.5.B). However, NRPSs are absent from flexus and coagulans 
groups (Figure 3.6.A).  The majority of the NRPS BGCs cluster with known compounds, 
and only 1140 BGCs, roughly 22% of the predicted NRPSs appear to be responsible for new 
compounds. In contrast to these well-described NRPS BGCs, the majority of PKS, 
lanthipeptide, and thiopeptide BGCs are unknown (Figure 3.5.B). Overall, there are far 
fewer PKS BGCs in Bacilli than NRPS BGCs, and PKSs are primarily present in the subtilis 
group strains (Figure 3.7.C). Type III PKSs are the predominate members, and the 
remaining BGCs are mostly Type I trans-AT PKSs with only a few exceptions.  Type II PKS 
BGCs are mostly absent from Bacillus species.  In Bacilli, we observed that hybrid NRPS-
PKS are more abundant than PKS BGCs (Figure 3.5.B). Zwittermicin, a Type I PKS/NRPS 
hybrid, accounts for the majority of all hybrid BGCs, while the remaining hybrid systems 
predominantly use Trans-AT PKS/NRPS machinery.  Similar to the NRPSs, the majority of 
hybrid NRPS-PKS BGCs from Bacilli are predicted to produce known compounds, but there 
is a small group (133 BGCs) that can be attributed to unknown and potentially new 
compounds.  Finally, canonical RiPPs (e.g. lanthipeptides and thiopeptides) have a much 
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smaller percentage of known members: we identify only five known compounds in the total 
1164 lanthipeptide BGCs, while the thiopeptides exhibit only one known representative in 
the 80 identified BGCs.  
 
Figure 3.5. Overview of Bacillus species and BGC diversity. A. Phylogenetic and chemical 
diversity of Bacillus species. Phylogenetic tree shows representative strains and colored 
boxes that designate species groups used throughout. Types and abundance of BGCs found 
within each species are shown in graph with total number of strains on the left and average 
number of BGCs per strain for each species on the right. B. Distribution of BGC totals and 
singletons by type along with overall percent of BGCs above a 75 horizontal gene transfer 
score. 
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Thus, depending on the metabolite class, many of the identified BGCs in our dataset 
appear to be conserved, or present in a significant proportion of strains, among the Bacilli.  
Most of the NRPS BGCs are highly conserved across different Bacillus species, indicating 
their importance to the genus. Correspondingly, these NRPSs show little evidence of HGT. 
Although the Bacillus PKSs are mostly attributed to unknown natural products (with the 
exception of zwittermicin, the only PKS identified in the cereus group), the few PKS BGCs 
that were found appear to be core constituents of the genus and show little evidence of HGT.  
Remarkably, essentially all of the unique singletons in our dataset (661 total BGCs) are 
attributed to unknown compounds, irrespective of their metabolite class. Many of these 
poorly conserved, rare BGCs scattered throughout the Bacillus genomes appear to have been 
acquired by HGT.  Below we discuss the known and highly conserved BGCs, unknown and 
highly conserved BGCs, and a handful of compelling examples of poorly conserved BGCs. 
 
3.6 Highly-Conserved, Known BGCs 
Many of the highly conserved BGCs in our dataset are NRPSs with a handful of 
hybrid NRPS-PKSs, such as zwittermicin and bacillaene, also being well conserved. 
Although several of these compounds have already been linked to important signaling roles 
in Bacilli, the native biological activities of many of them remains poorly understood. 
The most abundant NRPS BGC in the data set is the biosynthetic pathway for the 
siderophore bacillibactin, the primary iron scavenger for most Bacillus species (Figure 
3.6.B, cluster 2) (28). Bacillibactin was identified in 90.9 % of the public strains (200 
genomes) as well as 90.7 % of the AgBiome strains (1220 genomes). Of the remaining 146 
strains that lack bacillibactin, 130 were found to contain putative petrobactin BGCs.  
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Petrobactin is the primary siderophore in B. anthracis (29). With regards to the remaining 16 
strains, we hypothesize that either they generate alternative, unknown siderophores or they 
do not make their own siderophores, but instead ‘pirate’ the siderophores produced by other 
bacteria (30). 
 The second most-common group of NRPS BGCs clusters with the known kurstakin 
BGC.  These cyclic lipopeptides have been shown to control swarming and biofilm formation 
in B. thuringiensis (31). BGCs for the kurstakins were identified in 42.5 % of the public 
strains (94 genomes) and 50 % of the AgBiome strains (998 genomes).  These BGCs are only 
found in the cereus group and one strain from the ‘other’ group (Figure 3.6.B, clusters 3 and 
13). In addition to the high conservation of the six kurstakin biosynthetic genes, the amino 
acids incorporated by these synthetases are also highly conserved within our dataset strains, 
as variation was typically limited to the 6th amino acid.  
Bacillamide biosynthetic genes were unexpectedly common in the data set (Figure 
3.6.B, cluster 4).  To date, the algicidal bacillamides have only been isolated from marine 
Bacillus strains (32–34). However, this BGC was present in 45.7 % of the public strains (101 
genomes), and 42.8 % of the AgBiome strains (849 genomes). These BGCs were observed in 
B. thuringiensis, B. cereus, B. anthracis, B. mycoides, and several of the ‘other’ strains. 
Other than its algicidal properties and activity against one strain of cyanobacteria, little is 
known about whether bacillamides play signaling roles within the Bacilli. However, its 
prominence indicates that it may serve an important biological function in the cereus group 
in particular.  
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Figure 3.6 NRPS Complexity. A. The table shows the breakdown of percent of strains 
containing each type of NRPS by species group followed by percent BGCs above a 75 HGT 
score in parentheses. B. The network map visually shows the known (purple) and unknown 
(yellow) NRPS clusters with the cluster number in each node. The number of singletons is 
noted. C. Representative NRPS BGCs are indicated with NRPS genes in red. Structure and 
compound production of bacillamide and kurstakin are highlighted with their BGC. 
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 Zwittermicin (Figure 3.7.B, cluster 3) is an aminopolyol with broad-spectrum 
antibiotic activity that was first isolated from B. cereus (35). This Type I PKS/NRPS hybrid 
BGC has been identified in a number of Bacillus strains since then, and it appears in 8.1 % of 
the public strains (18 genomes) and 23.7 % of the AgBiome strains (319 genomes) (Figure 
3.7.C). Although common within these Bacillus strains, our data indicates that the 
zwittermicin BGC was likely acquired via HGT (Figure 3.7.C). Zwittermicin has been noted 
for its synergistic activity with other microbial metabolites. For instance, it synergizes with 
kanosamine to inhibit the growth of E. coli and oomycetes, and it was later discovered that in 
some strains the kanosamine biosynthesis genes are found within the zwittermicin BGC (36, 
37). Our dataset reveals that zwittermicin is also frequently associated with other BGCs, 
including three separate Class II lanthipeptides and a group of NRPS BGCs with a conserved 
CATCATR modularity. Although the products of these BGCs are unknown, their consistent 
integration into the zwittermicin cluster suggests potential synergistic or regulatory role.  
There are a number of other notable, highly-conserved and known NRPS-derived 
BGCs within our dataset. Specifically, the hybrid NRPS-PKS, bacillaene (Figure 3.7.B, 
cluster 20), and the NRPSs, surfactin and fengycin (Figure 3.6.B, clusters 29 and 27, 
respectively) are common among subtilis group members, while bacitracin (Figure 3.6.B, 
clusters 22 and 23) and cereulide (Figure 3.6.B, cluster 28) are predominantly found within 
cereus group members (Figure 3.6.A).  Many of the most well-known and characterized 
Bacillus NRPS metabolites, such as bacillibactin, bacillamide, cereulide, surfactin, and 
fengycin exhibit very low likelihood of HGT, at least within the cereus group (Figure 3.6.A). 
Two known compounds (kurstakin and bacitracin) showed high likelihood of having been 
acquired by HGT (Figure 3.6.A). 
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Figure 3.7. PKS Distribution. A. Network map for known (purple) and unknown (yellow) 
PKS clusters with the cluster number in each node, and the number of singletons listed. B. 
Network map for known (purple) and unknown (yellow) hybrid NRPS-PKS clusters with the 
cluster number in each node. C. Distribution of most abundant PKS BGCs between species 
groups showing the percent of strains containing that BGC with percent of strains above 75 
HGT score in parentheses. 
 
3.7 Highly-Conserved, Unknown BGCs 
A number of highly-conserved BGCs did not readily connect with known natural 
products in our analysis, suggesting that they may synthesize new compounds.  Two BGCs 
were particularly well-conserved, which included a group of NRPS BGCs with a conserved 
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CATCATR architecture and a group of Type III PKS, which had previously been 
hypothesized to make a series of alkylpyrones in B. subtilis. 
 The stringent parameters used in our analysis meant that the CATCATR BGC was 
split into a number of smaller DBSCAN clusters (Figure 3.6.B, clusters 5, 11, 12, 15, 17, 19, 
24, and 26, although cluster 11 groups separately from the others due to its unique genomic 
context). Although these BGCs were found in 5.4 % of public strains (12 genomes) and 24.4 
% of AgBiome strains (316 genomes), this BGC remains largely uncharacterized. Its NPRS 
gene architecture suggests that it generates a modified dipeptide, which may be structurally 
related to a series of diketopiperazines recently found to regulate virulence in Staphylococcus 
aureus (38)(39).   Notably, these BGCs show a high likelihood of having been acquired via 
HGT (Figure 3.6.A). 
Even though PKSs are relatively rare in the Bacillus genomes, a two-gene, Type III 
PKS appeared widely distributed (Figure 3.7.A, clusters 11, 12, 15, 16, 17, 18, 22, 27, 36, 
37, 38, 40, 41, and 42).  The structure of this compound was first suggested in 2009 based on 
homologous overexpression of the two biosynthetic genes, bpsA and bpsB (40). This 
approach yielded a number of triketide pyrones as well as small amounts of tetraketide 
alkylresorcinols with varying chain length, but no native expression could be detected (40).  
Similar molecules isolated from Azotobacter vinelandii and Streptomyces griseus were 
implicated in cyst formation and beta-lactam resistance, respectively, but no function could 
be ascribed to these putative alkylpyrones from B. subtilis (41, 42). The bpsA-bpsB operon is 
particularly well-distributed among subtilis group strains, being found in B. 
amyloliqueifaciens, B. atrophaeus, B. flexus, B. subtilis and B. megaterium strains. Moreover, 
15 % of the publically available genomes and 5 % of the AgBiome genomes possess this 
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BGC. The prevalence of this operon suggested that the products might have an important 
biological function within the Bacilli.  We tested this prediction, and will describe below, for 
the first time, a role for the bpsA-bpsB operon in Bacillus physiology, impacting both biofilm 
formation and sporulation. 
 
3.8 Unique, singleton BGCs 
Given the limited number of natural products that have been isolated from Bacillus, 
we identified a remarkably large number of unknown BGCs in the data set. The majority of 
these unknown BGCs comprise unique singletons that did not cluster with any other BGC, 
and some were so rare that they did not connect with the rest of the network map. Certain 
strains of Bacilli contained more distinct ‘singletons’ than others.  For example, a strain of 
Bacillus pseudomycoides in particular possesses eight unknown singletons (Figure 3.8). 
These highly unusual BGCs are potentially promising leads for discovery of new compounds 
and biological activities.  
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Figure 3.8. Bacillus superproducers of distinct ‘singleton’ BGCs.  The graph shows the 
distribution of strains containing one or multiple singletons. 
 
One unexpected rare find in the Bacillus genomes was a small set of type II PKS 
BGCs.  Although a number of polyketides have been isolated from Bacilli, they are 
predominantly of the extended, linear form, common to type I and III PKSs. There have been 
few reports of the polyaromatic type II polyketides outside the Actinomycetes and none from 
Bacilli. We identified four unique Type II PKSs within Bacillus genomes from the AgBiome 
strains (two B. cereus, one B. megaterium, and one B. mycoides strains). The two easily 
identifiable ketosynthase PKS genes in these BGCs show approximately 45 % homology to 
BGCs in a parcubacterial strain, the cyanobacterium Gloeobacter violaceus, and a number of 
Delftia species. In addition to these two ketosynthase genes, these BGCs also contain 
0
10
20
30
40
50
60
70
80
90
100
1 2 3 4 5 6 7 8
N
um
be
r o
f S
tr
ai
ns
Number of Singletons
370
380
Figure S6
 73 
multiple genes responsible for other structural modifications. The metabolites produced by 
these BGCs are completely unknown, and it is likely that the presence of these BGCs is due 
to HGT.  
Lanthipeptides and thiopeptides in particular represented a disproportionate number 
of these weakly conserved, new compounds.  Lanthipeptides are characterized by lanthionine 
or methyllanthionine bridges formed by a thioether linkage between two alanine residues (43, 
44).  In Streptomyces, SapB, the canonical lanthipeptide, has been shown to play a critical 
role in development of aerial mycelia (45). Similarly, lanthipeptides could have important 
signaling roles in Bacilli. Lanthipeptides proved to be abundant in Bacillus genomes. We 
identified lanthipeptide BGCs in 45 % of public strains (100 genomes) and 79 % of 
AgBiome strains (1064 genomes) (Figure 3.9.A), but they are highly under-studied with 
only five of these BGCs associated with a known natural product.  Most of these BGCs are 
class I and class II lanthipeptides from the B. cereus group, although at least one 
lanthipeptide can be found in every phylogenetic group (Figure 3.9.C). Additionally, our 
analysis predicts a handful of the substantially less common class III and IV lanthipeptides, 
as well as some severe outliers with unique combinations of multiple, small type II enzymes.  
A few lanthipeptides produced by Bacilli have been studied for their antibiotic activity 
against Gram-positive organisms. The ceredins, lanthipeptides from the cereus group, are 
hypothesized be produced during competence in late exponential phase and haloduracin, a 
lanthipeptide produced by B. halodurans, can inhibit B. anthracis spore outgrowth (46). 
Little else is understood about the roles of this metabolite class in Bacilli, but their 
prominence suggests a significant role in the genus. 
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Thiopeptides are macrocyclic peptides containing thiazoles.  They are cyclized 
through a nitrogenous ring that can adopt a variety of oxidation states, and often contain 
dehydrated residues (43). Thiopeptides have historically been found in Streptomycete 
species, while only one thiopeptide (thiocillin) is a known product of a Bacillus species (B. 
cereus ATCC 14579) and was recently found to play a role in biofilm induction (19). We 
identified a total of 79 new thiopeptide BGCs in these Bacillus genomes. Many of these 
Bacillus thiopeptides possessed unique and remarkably diverse precursor peptide sequences 
compared to those present in previously characterized thiopeptides (Figure 3.9.B).  It will be 
interesting to see if these new thiopeptides play similar roles as the thiocillins from B. cereus 
ATCC 14579. 
In addition to these highly-conserved BGCs, we also identified a number of unique, 
weakly conserved BGCs across all species and BGC classes. Some of these were entirely 
distinct ‘singletons’ while others were BGCs that were conserved in only a small number of 
strains (i.e. the unknown NRPS BGCs, present in < 5 % of the cereus strains; many of the 
RiPPs). The majority of these BGCs seem to have been acquired through horizontal gene 
transfer, particularly the singletons. These BGCs are quite diverse and offer avenues for 
identifying new and distinct natural products that appear to occupy untapped niches of 
chemical space. Our analysis further suggests that these metabolites may similarly exhibit 
previously unknown biological activities that impact the physiology and ecological 
interactions of the producing bacteria. 
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Figure 3.9. Lanthipeptide and thiopeptide RiPPs Example. A. Network map for 
lanthipeptides and thiopeptides with the number of BGCs in each node. Colors indicated 
lanthipeptide class, thiopeptide, or unclassified. Dual BGCs have machinery for more than 
one class. The number of singletons is listed. B. Alignment of thiopeptide precursor peptide 
sequences showing sequence diversity compared to known thiopeptides from Streptomycetes. 
C. Distribution of lanthipeptides by class for the various species groups showing the percent 
of strains containing that class of RiPP with percent of strains above a 75 HGT score in 
parentheses. 
 
3.9 Alkylpyrone signaling activity 
Many of the BGCs identified in our extensive Bacillus genome database are 
unknown, while most of the highly conserved BGCs have already been shown to have 
important roles impacting bacterial physiology. We hypothesized that other conserved but 
uncharacterized BGCs might also act as signals and have physiological effects on Bacillus. 
Thus, we examined the bpsA-bpsB operon, generated by the most common PKS BGC, for 
potential biological activity.  
Products of the bpsA-bpsB operon have never been isolated from wild-type strains.  
Moreover, efforts to assign biological function to putative compounds isolated from 
engineered over-producing strains have not been able to uncover activity.  Two of the best-
studied phenotypes of Bacillus species are their ability to form distinctive biofilms on solid 
agar (47) and their ability to sporulate, which are often co-regulated (13).  When we 
examined the SubtiExpress database (48) for clues about the potential biological function of 
this operon, we observed that transcription of bpsA (the type III PKS in the BGC), is 
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upregulated during sporulation.  We therefore grew B. subtilis 3610, a model Bacillus strain, 
in MSgg, a biofilm-inducing media, for 72 hours, in order to allow B. subtilis to sporulate 
(47). LCMS analysis showed production of alkylpyrones with C15 side chains in wild-type B. 
subtilis (Figure 3.10). To further probe the biological activity of these alkylpyrones, we 
synthesized two variants that we identified from B. subtilis that had straight C15 chains, but 
one was methylated at the 4-hydroxy position (Scheme 3.1 and Figure 3.11) (See Appendix 
B for NMR characterization).  
 
Figure 3.10. Alkylpyrone BGC architecture, structure, and LCMS from Bacillus subtilis. 
 
 
Scheme 3.1. Synthesis of alkylpyrones. 
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Figure 3.11. Characterization of alkylpyrone OH (A) and alkylpyrone OMe (B), including 
UV and high-resolution LCMS. 
 
We tested a panel of Bacilli comprised of representative members from 13 different 
species (Table 3.1) and grown on two different media (LB and MSgg) in the presence of 
either of the two purified alkylpyrones or a DMSO solvent control (Figure 3.12.A). No 
effect could be seen in presence of the unmethylated alkylpyrone. However, the 4-hydroxyl 
alkylpyrone affected biofilm colony morphology of B. subtilis 3610 on MSgg, and B. 
amyloliquefaciens and B. coagulans on LB.  In all cases we observed a hyper-wrinkling in 
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the center of the colonies as well as other, more delicate morphological changes (Figure 
3.12.A). It has been previously reported that hyper-wrinkling in B. subtilis biofilms is due to 
increased cell death (49), but our data indicates that the 4-hydroxyl alkylpyrone does not 
impact growth of these three strains (Figure 3.13).  It does however kill two other Bacillus 
strains (Figure 3.13). Whether the observed effects are due to localized cell death or not, 
these data indicate that 4-hydroxyl alkylpyrone functions as a signal that impacts biofilm 
colony morphology within multiple Bacillus species. 
 
Table 3.3. Strains tested in phenotypic screen. 
 
 Given the timing of bpsA expression in B. subtilis and the regulatory relationship 
between biofilm formation and sporulation, we also thought to investigate a potential role for 
these alkylpyrones in sporulation. We tested effects of both alkylpyrone variants on B. 
subtilis sporulation by adding compound or DMSO control to cells in liquid MSgg and 
monitoring the percentage of spores formed over time. Both alkylpyrones delayed 
Species Strain 
B. subtilis NCBI3610 
B. atrophaeus 1942 
B. amyloliquefaciens NRRL B-14393; BGSC 10A5 
B. cereus ATCC 14579 
B. clausii BGSC 15A4T, NRRL B-23342 
B. coagulans ATCC 7050; BGSC 60A1 
B. halodurans C-125 
B. licheniformis ATCC 10716 
B. megaterium ATCC 14581; BGSC 7A36 
B. mycoides WSBC 10277; BGSC 6A47 
B. pumilus ATCC 7061 
B. thuringiensis BGSC 4BD1 
B. weihenstephanensis WSBC 10364; BGSC 6A50 
 
Table S3
 80 
sporulation at day 2 compared to the DMSO control (Figure 3.12.B) at concentrations that 
did not affect growth (Figure 3.13). However, by day 3 the percent of spores formed was 
comparable to the DMSO control (Figure 3.12.B).  
 
Figure 3.12. Alkylpyrone biological activity. A) Phenotypic changes in Bacilli in response to 
alkylpyrones. All three strains show increased wrinkling in the center when treated with 
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alkylpyrone OH. B) Alkylpyrones delay sporulation in Bacillus subtilis at 49 hr. Samples 
taken with n = 7 and the error bars show standard deviation. 
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Figure 3.13. Alkylpyrones do not affect growth. Growth curve of Alkylpyrone OH treated 
samples (A) or the full growth curve of the three Bacilli with strong phenotypes (B).  Total 
CFUs taken during spore counts with N = 6 (C). 
 
 The Bacillus alkylpyrones have structural similarity to the germicidins from 
Streptomycetes as they have the same 2-pyrone core but differing alkyl substituents. 
Germicidins are known to delay germination of Streptomycete spores (50, 51).  We therefore 
wanted to assess whether the alkylpyrones might also impact germination of either Bacillus 
or Streptomyces spores. We tested this by counting the colony forming units resulting from 
spreading B. subtilis spores on rich media containing the alkylpyrones and monitoring S. 
coelicolor germination in fresh liquid media by absorbance and phase-contrast microscopy 
(52). Neither case gave any evidence of the alkylpyrones affecting germination (Figure 
3.14). Thus, like the germicidins, alkylpyrones seem to regulate sporulation, but by delaying 
sporulation rather than by impacting germination. 
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Figure 3.14. Alkylpyrones do not affect germination. Germination assay for Bacillus subtilis 
(A) and Streptomyces coelicolor (B) spores treated with alkylpyrones. Images at t = 6 hrs.  
Absorbance and CFUs were measured with n = 3 each. 
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3.10 Summary 
 We have pursued an intensive bioinformatics analysis of the genus Bacillus to 
measure its chemical diversity and better understand the scope and role of specialized 
metabolites.  A unique feature of our analysis is the number of genome sequences from a 
single genus that were included. By examining 1,566 genomes, we have evaluated nearly five 
times more sequences than the previously published analysis of the Bacillus genus (20).  This 
depth of sequence information gave us more insights than what we could have gleaned from 
a smaller population.  This is consistent with previous studies (53, 54) that expanding the 
genomic content of bacterial strains reveals new insights in specialized metabolite diversity 
and function.   
B. subtilis is known to have a complex developmental lifecycle (55). Some of its 
cellular differentiation occurs in response to specialized metabolites (13). Specialized 
metabolites that function as signals in the Bacillus lifecycle, including the newly 
characterized alkylpyrones, are summarized in Figure 3.15.  The results of our analysis 
indicate Bacilli have the biosynthetic machinery for a set of characteristic, highly-conserved 
compounds across the genus or within individual groups.  These compounds play either 
known or currently unknown roles in signaling and bacterial development within Bacilli and 
across interspecies interactions.  While several of the most prominent compounds have 
known constituents that have been studied, such as bacillibactin and kurstakin, many other 
prolific BGCs are uncharacterized or have no known biological activity.  There is more work 
to be done in beginning to tease apart the roles and interactions in which these compounds 
are involved. We looked at the understudied Type III PKS group, the alkylpyrones, to begin 
to answer questions about the function of these compounds.  Although an engineered strain 
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had provided partial evidence of the structure of this compound, it had not been produced in 
its native host and no biological function could be assigned. Based on published expression 
data, conditions were found that elicited production of the alkylpyrone BGC in B. subtilis.  
Based on expression data and the similarity to the known germicidin compounds from 
Streptomycetes, we hypothesized that the alkylpyrones might have a role in sporulation.  We 
tested two alkylpyrone compounds for biological activity in sporulation and both delayed the 
onset of sporulation.  Other compounds have been shown to delay sporulation, including the 
Bacillus peptide SDP (sporulation delaying protein) (56) and 2,4-diacetlyphloroglucinol 
(DAPG), a metabolite produced by Pseudomonas protegens (57).  However, both have been 
shown to cause cell lysis and death (58). Thus, the alkylpyrones are the first identified 
specialized metabolite that delays the process of sporulation without inhibiting growth.  
 
Figure 3.15. Bacillus lifecycle highlighting the signaling specialized metabolites that 
mediate each step.  Compounds are noted as promoting (arrow) or delaying (flat-end), and 
question marks indicate where no metabolite has yet been assigned a signaling role. 
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 In addition to highly conserved BGCs, we also identified a number of unique, weakly 
conserved BGCs scattered across all species and BGC classes. Some of these were distinct 
‘singletons’ while others were BGCs that were conserved in a small number of strains.  For 
example, the unknown NRPS BGCs that are present in < 5 % of the cereus strains and many 
of the RiPPs. The majority of these BGCs seem to have been acquired through horizontal 
gene transfer. These BGCs are quite diverse and offer leads for identifying new and distinct 
natural products that appear to occupy new chemical space. Our analysis further suggests that 
these metabolites may similarly exhibit previously unknown biological activities that impact 
the physiology and interactions of the producing bacteria.  
 
3.11 Experimental 
3.11.1 General Methods 
 All reactions were carried out in an oven-dried round-bottomed-flask under an inert 
nitrogen atmosphere. Solvents and reagents were used as received unless otherwise noted. 
Spectra for 1H and 13C NMR were recorded at room temperature with a Varian Inova 400 
(400 MHz and 100 MHz, respectively). Chemical shifts are reported in δ (ppm) relative units 
to residual solvent peak CDCl3 (7.26 ppm for 1H and 77.0 ppm for 13C).  Splitting patterns 
are assigned as s (singlet), d (doublet), t (triplet), q (quartet), p (pentet), and multiplet (m). 
Mass spectrometry measurements were recorded using an Agilent 6520 Accurate-Mass Q-
TOF ESI positive in high-resolution mode. Flash chromatography was performed on a 
Biotage IsoleraTM system with a hexanes/ethyl acetate solvent system or a 
dichloromethane/methanol system.  Thin-layer-chromatography glass plates were purchased 
from Sorbent Technologies, Inc.® with a fluorescent indicator at 254 nm.  
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3.11.2 Synthesis 
1-(1H-benzo[d][1,2,3]triazol-1-yl)hexadecan-1-one was prepared according to the 
literature method (59). Benzotriazole (2.4 g, 20 mmol, 4 equiv.) was dissolved in 25 mL of 
DCM.  Thionyl chloride (0.365 mL, 5 mmol, 1 equiv.) was added and the reaction was 
stirred for 30 min at rt.  Palmitic acid (1.28 g, 5 mmol, 1 equiv.) was then added and the 
reaction was stirred for 2 hr at rt.  Mixture was filtered to remove white precipitate, which 
was washed with DCM (2 x 50 mL).  The organic solution was washed with aq. 2 N NaOH 
(3 x 60 mL), dried with anhydrous Na2SO4, and concentrated under reduced pressure to 
dryness. Compound was purified by flash chromatography with silica gel (~60 mesh) with a 
hexanes (Hex) / ethyl acetate (EtOAc) mixture (Rf = 0.25, 5% EtOAc in Hex) to afford the 
product in 70% overall yield. 1H NMR (400 MHz, Chloroform-d) δ 8.24 (d, J = 8.3 Hz, 1H), 
8.06 (d, J = 8.4 Hz, 1H), 7.59 (t, J = 7.8 Hz, 1H), 7.44 (t, J = 7.8 Hz, 1H), 3.37 (t, J = 7.5 Hz, 
2H), 1.86 (p, J = 7.6 Hz, 2H), 1.51-1.37 (m, 2H), 1.21 (s, 24H), 0.83 (t, J = 6.7 Hz, 3H).  
 
2,2-dimethyl-6-(2-oxoheptadecyl)-4H-1,3-dioxin-4-one was prepared according to a 
literature method (60).  2,2,6-trimethyl-4H-1,3-dioxin-4-one (0.106 mL, 0.8 mmol, 1.134 
equiv.) was dissolved in THF (3.5 mL) at -80 oC.  Lithium diisopropylamide (0.455 mL, 0.91 
mmol, 1.3 equiv.) was added and the reaction was stirred for 1.5 hr. 1-(1H-
benzo[d][1,2,3]triazol-1-yl)hexadecan-1-one (0.25 g, 0.7 mmol, 1 equiv.) was added in 3.5 
mL of THF and the reaction was stirred and let warm to rt overnight.  The reaction was 
quenched with 10 mL of sat. aq. ammonium chloride and concentrated under reduced 
pressure to remove THF. The remaining mixture was extracted with EtOAc (3 x 25 mL), 
dried with anhydrous Na2SO4, and concentrated under reduced pressure to dryness. 
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Compound was purified by flash chromatography with silica gel (~60 mesh) with a hexanes 
(Hex) / ethyl acetate (EtOAc) mixture (Rf = 0.5, 20% EtOAc in Hex) to afford the product in 
32% overall yield. 1H NMR (400 MHz, Chloroform-d) δ 5.29 (s, 1H), 3.27 (s, 2H), 2.44 (t, J 
= 7.5 Hz, 2H), 1.67 (d, J = 3.7 Hz, 6H), 1.51-1.37 (m, 2H), 1.21 (s, 24H), 0.83 (t, J = 6.8 Hz, 
3H). 
 
4-hydroxy-6-pentadecyl-2H-pyran-2-one was prepared according to a literature 
method (60).  2,2-dimethyl-6-(2-oxoheptadecyl)-4H-1,3-dioxin-4-one (0.04 g, 0.11 mmol, 
1.0 equiv.) was dissolved in toluene (5 mL) and allowed to reflux at 135 oC for 30 min.  The 
reaction was concentrated under reduced pressure to dryness. Compound was purified by 
flash chromatography with silica gel (~60 mesh) with a dichloromethane (DCM) / methanol 
(MeOH) mixture (Rf = 0.25, 5% MeOH in DCM) to afford the product in 32% overall yield. 
NMR values match what is reported in the literature (40). 1H NMR (400 MHz, Chloroform-
d) δ 5.87 (d, J = 2.3 Hz, 1H), 5.48 (d, J = 2.1 Hz, 1H), 2.49 – 2.40 (m, 2H), 1.62 (q, J = 7.6 
Hz, 2H), 1.24 (s, 24H), 0.90 – 0.82 (m, 3H).  
 
4-methoxy-6-pentadecyl-2H-pyran-2-one was prepared according to a literature 
method (61).  K2CO3 (0.023 mg, 0.169 mmol, 5.7 equiv.) was dissolved in acetone (2 mL) 
and dimethyl sulfate (0.0037 mL, 0.039 mmol, 1.3 equiv.) was added.  4-hydroxy-6-
pentadecyl-2H-pyran-2-one (0.010 g, 0.03 mmol, 1.0 equiv.) was dissolved in 1 mL of 
acetone and added to the reaction mixture.  The reaction was stirred for 16 hours at rt.  
Mixture was filtered to remove white precipitate, which was washed with acetone (2 x 20 
mL), and concentrated under reduced pressure to dryness. Compound was purified by flash 
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chromatography with silica gel (~60 mesh) with a dichloromethane (DCM) / methanol 
(MeOH) mixture (Rf = 0.25, 2% MeOH in DCM) to afford the product in 46% overall yield. 
NMR values match what is reported in the literature (40). 1H NMR (400 MHz, Chloroform-
d) 5.74 (d, J = 2.3 Hz, 1H), 5.38 (d, J = 2.0 Hz, 1H), 3.77 (s, 3H), 2.41 (t, J = 7.6 Hz, 2H), 
1.60 (q, J = 7.2 Hz, 2H), 1.23 (s, 24H), 0.86 (m, 3H).  
 
3.11.3 Genome Sequencing  
DNA was isolated from cell pellets from isolated, cultured strains using MOBio 
Microbial DNA isolation Kit followed by quantification using a Quant iT Picogreen assay. 1 
ng of quantified DNA was sheared enzymatically at 55 °C for 5 minutes using the Illumina 
Nextera XT Tagmentation enzyme. Tagmented DNA fragments were enriched by 10 cycles 
of PCR amplification using PCR master mix and primers with index from Illumina. Libraries 
were quantified by the KAPA SYBR FAST qPCR kit and pooled at a 4 nM concentration. 
Libraries were denatured with 0.2 N NaOH and sequenced on an Illumina Hiseq Sequencing 
platform.  Illumina Paired End reads were demultiplexed using Illumina software bcl2fastq 
v2.18.0.12.  Paired End reads are adapter and quality trimmed using cutadapt version 1.5 
recommended by Illumina. Trimmed Paired End reads are assembled and reads are aligned 
back to the consensus sequence using the CLC Genomics programs CLC Assembly Cell and 
CLC Mapper from QIAGEN. 
 
3.11.4 Biosynthetic Gene Cluster Prediction and Comparison 
antiSMASH was used with default parameters to predict BGCs present in each 
genome. All BGCs were then divided into individual GenBank files, and an initial pairwise 
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similarity matrix was calculated using MGB with default parameters to produce scores, based 
on an algorithm unique to MGB, between every possible BGC pair. Scores between every 
given pair of BGCs were averaged as they could differ depending on the direction of the 
comparison. This produced a “lower left” similarity matrix that was then normalized by 
dividing each column of values by the maximum value in the respective column. This was 
then converted to a distance matrix by inverting the values. Sub-matrices were produced for 
each type of BGC based on antiSMASH assignment. 
 
3.11.5 Clustering of Biosynthetic Gene Clusters   
The DBScan implementation available in the R fpc library was used in conjunction 
with the previously produced sub-matrices to cluster BGCs. DBScan parameters were 
optimized by iteratively running DBSCAN and varying the EPS by 0.01 (from 0.01 to 0.98) 
and MinPts by 1 (from 2 to 15) in every combination. The resulting cluster listings were 
compared to the graphic alignments from MultiGeneBlast. In most cases, MGB alignments 
would quickly deteriorate, and those DBSCAN parameters that best discriminated at these 
borders were chosen. Those alignments corresponding to known BGCs were most heavily 
considered in DBScan parameter optimization.   
 
3.11.6 Silhouette Coefficient Calculations 
The Silhouette Coefficient is calculated using the mean intra-cluster distance (a) and 
the mean nearest-cluster distance (b) for each sample. The Silhouette Coefficient for a 
sample is (𝑏 − 𝑎)/max⁡(𝑎, 𝑏) (25). To clarify, b is the distance between a sample and the 
nearest cluster that the sample is not a part of.  
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3.11.7 Strains 
All strains tested for phenotypes and other public strains were from our laboratory 
collection. The non-public strains used in the LCMS analysis came from AgBiome. 
 
3.11.8 Growth Curves 
All strains used in the phenotypic screen were resuspended in Luria–Bertani (LB)-
Lennox (10 g tryptone, 5 g yeast extract and 5 g NaCl per liter) to an OD600 of 0.05 and 150 
µL was transferred to a 96-well plate. Compound was added at 50 µM in DMSO. The plate 
was shaken at 30 °C and 350 rpm, while absorbance measurements were taken on an Infinite 
m200 Pro Tecan. 
 
3.11.9 Phenotypic Screens 
The alkylpyrone compounds were tested against 13 strains of Bacilli (Table 3.3) on 
Lennox LB and MSgg (5 mM potassium phosphate [pH 7], 100 mM 
morpholinepropanesulfonic acid [MOPS; pH 7], 2 mM MgCl2, 700 μM CaCl2, 50 μM 
MnCl2, 50 μM FeCl3, 1 μM ZnCl2, 2 μM thiamine, 0.5% glycerol, 0.5% glutamate) with 
1.5% (wt/vol) agar.  Plates were poured with a Wheaton Unispense liquid dispenser to 20 mL 
for LB or 30 mL for MSgg.  All liquid media was the same composition, but without the 
agar.  S. coelicolor was grown on Soy Flour Mannitol (SFM) agar (2% soy flour, 2% 
mannitol, 1.5% agar) or in Glucose Yeast extract Malt extract (GYM) liquid medium (0.4% 
glucose, 0.4% yeast extract, 1% malt extract). Plates were first spotted with 2.5 µL of 100 
µM compound, and then 1 µL of cells at OD600 of 0.5 were spotted on top of the dried 
compound. Plates were incubated at 30 °C and photos were taken at 72 hours. The images 
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shown are the strongest phenotypes across all combinations, and were representative of three 
biological replicates. 
 
3.11.10 Spore Counts 
Spore counts were taken for B. subtilis 3610 in the presence of 50 µM compound. 
Bacillus subtilis was grown in 3 mL of LB broth at 37 °C to an OD600 of 1.0. The culture was 
diluted 0.2 µL in 1 mL of MSgg broth and compound was added in DMSO to 50 µM before 
growing at 30 °C and 200 rpm. At each time point, 100 µL of culture was sonicated using a 
protocol verified to separate cells from one another without lysing them (62) (on a Branson 
Digital Sonifier for 12 sec and 15% amplitude with a pulse of 1 second on and 1 second off). 
Half of the sample was set aside and the other half was heated at 80 °C for 30 minutes. The 
samples were serially diluted in LB broth and grown on LB plates for colony counting the 
next day using 6 biological replicates.  
 
3.11.11 Bacillus subtilis Germination Assay 
B. subtilis was grown under the same conditions as for spore counts. At 49 hours, the 
sample was sonicated, heat treated to kill vegetative cells, and serially diluted using the same 
method as for spore counts.  The sample was grown on LB plates containing 50 µM of either 
compound or DMSO to count the colonies that would germinate in the presence of 
compound.   
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3.11.12 Streptomyces coelicolor Spore Isolation 
S. coelicolor was grown on SFM agar for 5 days at 30 °C until plate was covered in 
tan spores. Spores were gently scraped off the plate using an inoculating loop and 
resuspended in 5 ml of water. The spores were washed 3 times by pelleting and resuspending 
in 3 ml water before filtration through Miracloth to remove any mycelia. Spores were heated 
at 50 °C for 10 mins to kill any vegetative cells and stored in water at 4 °C.  
 
3.11.13 Streptomyces coelicolor germination assay 
Absorbance measurements for germination were done by diluting spores 1:10 in 
GYM media in a 96-well plate with 50 µM compound in DMSO. The plate was shaken at 30 
°C and 300 rpm, while absorbance measurements were taken on an Infinite m200 Pro Tecan. 
The assay was run in triplicate. 
 
3.11.14 Microscopy  
At each time point, 5 µL of germinating spores were spotted on a 1 % agar pad on a 
glass slide and covered with a cover slip. Images were acquired on a Nikon Eclipse 80i 
microscope with a 40X objective. 
 
3.11.15 Statistics 
The P values were calculated with a Tukey’s honest significant difference test using 
JMP Pro 12 software. 
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3.11.16 Growth Conditions and Extractions for LCMS Evaluation  
All AgBiome strains for kurstakin production were grown in 3 mL of LB at 30 °C in 
a roller drum incubator for 72 hours. Cells were pelleted at 4,000 rpm, resuspended in 0.5 mL 
of methanol and allowed to sit at least 1 hour for extraction. Cells were pelleted again at 
15,000 rpm and the resulting methanol supernatant was diluted 1:10 in 1:1 acetonitrile:water 
for injection on the LCMS. All AgBiome strains for bacillamide production and public 
strains were grown in 50 mL of LB at 30 °C and 200 rpm for 30 hours. For alkylpyrone 
production, B. subtilis was grown in 50 mL of MSgg at 30 °C and 200 rpm for 72 hours. For 
extraction, the cells were pelleted at 4,000 rpm for 25 minutes and sonicated using a Branson 
Digital Sonifier for 20 sec and 30% amplitude with a pulse of 0.5 second on and 1.5 seconds 
off.  The pH was adjusted to 2 using HCl before extraction with 1 mL of ethyl acetate for at 
least 1 hour. Cells were pelleted again at 15,000 rpm for 5 mins and the ethyl acetate was 
diluted 1:10 in 1:1 acetonitrile:water for injection on the LCMS.  
 
3.11.17 LCMS 
All LCMS data was obtained on an Agilent 6520 Accurate-Mass Q-TOF mass 
spectrometer with an electrospray-ionization source in positive ion mode. A 250 V 
fragmentor voltage was used with a 350 °C drying gas temperature. The extracts were run on 
a reverse-phase kinetex column using the following method: acetonitrile with 0.1 % formic 
acid was run as a gradient from 2 % to 100 % over 15 min and held at 100 % for 2 min with 
water containing 0.1 % formic acid. As controls, we also examined the extracts of 31 
AgBiome strains not predicted to possess bacillamide BGCs. Four bacillamides have been 
previously isolated (bacillamides A-D, which are tryptamide thiazole-containing compounds 
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(Figure 3C)), in addition to neobacillamide A, which contains a phenethylamine moiety 
instead of tryptamine, and verified production of all four bacillamides in Bacillus atrophaeus 
1942. 
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CHAPTER IV 
BACILLUS SUBTILIS AS A HETEROLOGOUS PLATFORM FOR PEPTIDE DRUG 
DISCOVERY 
4.1 Introduction 
The rising incidence of resistance to current antibiotics has become one of the world’s 
leading health problems: new antibiotics are desperately needed for the treatment of 
infectious disease.  Historically, natural products (or specialized metabolites) have been an 
essential source of new antibiotics; they offer chemical diversity unparalleled in the synthetic 
realm.  Although natural products have been studied for decades, they remain a rich source 
for novel chemical scaffolds that circumvent current antibiotic resistance pathways (1, 2).  
Bacillus species produce a wide array of natural products (Figure 4.1), although their vast 
biosynthetic potential has been largely underexplored.  The most famous Bacillus antibiotic 
that is in use is bacitracin (Figure 4.1), which is administered topically and is a key 
ingredient of Neosporin. 
Advances in genome mining have greatly increased our knowledge about the 
untapped chemical wealth available in bacterial secondary metabolomes (3, 4).  The natural 
grouping of biosynthetic genes, or gene clusters, in bacterial genomes allows for the rapid 
identification of new biosynthetic pathways that could lead to new natural product antibiotics 
(5).  Recent improvements in the identification of biosynthetic pathways for both 
ribosomally-synthesized and non-ribosomally synthesized peptides highlight the therapeutic 
 102 
potential in both newly discovered and well-studied organisms, yet reliably accessing these 
potential new drugs is still a major challenge in metabolic engineering (6).  
 
Figure 4.1. Structures of diverse Bacillus natural products. 
 
Traditional cultivation techniques typically fail to elicit many new or ‘cryptic,’ 
unexpressed gene clusters of interest (7).  Modifications in media composition or growth 
conditions have been effective in certain cases, but these methods are laborious with high 
rates of rediscovery (8).  Increasingly, genetic manipulation is being recognized as the most 
robust way to access these new compounds (9).  Unfortunately, even genetic manipulation is 
time-consuming and exhibits poor reproducibility in many relevant organisms (9, 10), 
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creating a need for more simplified and robust methods to access cryptic or unexpressed gene 
clusters of therapeutic interest (7, 10). Traditionally, a majority of natural product scaffolds 
have been discovered in Streptomyces species, which grow at much slower rates and are less 
amenable to genetic modification (10).  Heterologous expression of Streptomyces gene 
clusters has proven labor-intensive, often requiring one or two species, such as E.coli or 
yeast, for assembly before expression in the final heterologous host (11). Bacillus subtilis 
168 is a well-studied organism that can potentially solve this bottleneck.  B. subtilis is well-
suited as a heterologous host for several reasons: it has codon flexibility, is readily 
genetically manipulable, and is fast growing (12, 13).  Additionally, B. subtilis is naturally 
competent and highly recombinogenic, which allows it to easily take in large fragments of 
foreign DNA and stably integrate that DNA into its genome (13). A robust Bacillus subtilis 
heterologous expression platform will streamline genetic manipulations.  By using rapid 
cloning techniques to assemble linear pieces of DNA that can be directly transformed into B. 
subtilis, we can eliminate the need for plasmids or secondary species. Previous examples of 
cloning entire biosynthetic pathways into Bacillus subtilis have always used a secondary 
species for DNA assembly, either E. coli with the O-Red system or yeast with transformation-
associated recombination (TAR) (13–15).  Additionally, B. subtilis has a doubling time of 
about thirty minutes, grows at a range of temperatures, and readily exports molecules, 
leading to quick cultivation time (12, 13).  Thus, heterologous expression of a gene cluster in 
B. subtilis can be accomplished in a matter of days, in comparison to other platforms that 
may take weeks or months. 
Once clusters have been heterologously expressed in B. subtilis, they are amenable to 
further modifications to produce potentially more bioactive variants.  Making mutant 
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libraries of the heterologously expressed structural gene that becomes the final compound, 
combined with the incorporation of unnatural amino acids will allow us to use Bacillus 
subtilis to more readily access unique compounds of interest. Additionally, we have done 
extensive bioinformatics analysis on Bacillus genomes, and can take advantage of the 
plethora of uncharacterized clusters we have uncovered (See Chapter III). This analysis has 
allowed us to identify and prioritize biosynthetic pathways that could lead to unique natural 
products that have new biological activities (Figure 4.2 and Figure 4.3).   
 
Figure 4.2. Unique sequences of ‘cryptic’ thiopeptide precursor peptides from Bacillus 
compared to known sequences. 
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Figure 4.3. Unique biosynthetic gene clusters and sequences of ‘cryptic’ precursor peptides 
from Bacillus compared to known metabolite thiocillin (produced by Bacillus cereus ATCC 
14579). 
 
4.2 Strategy for heterologous expression 
 Our strategy uses next generation methods for DNA fragment assembly to increase 
speed and effectiveness of large scale cluster manipulation.  This approach utilizes the highly 
competent and recombinogenic nature of B. subtilis.  We piece together linear DNA and 
transform it directly into Bacillus subtilis without any intermediate hosts.  We developed this 
platform so that we would integrate the bulk of the biosynthetic gene cluster in a site similar 
to its location in its native host, and have been using AmyE for integration of structural 
genes.  By building plasmids with AmyE homology and the structural genes separately, it is 
easier to make mutations to the natural product without much cloning effort. 
The cloning strategy for DNA fragment assembly and transferring entire biosynthetic 
gene clusters revolves around Gibson assembly. We amplify the entire biosynthetic gene 
cluster in as few fragments as possible (usually 1-2 pieces), and use Gibson assembly to 
attach regions of homology to the B. subtilis genome and an antibiotic resistance marker.  
Gibson assembly, which uses a cocktail of enzymes to ligate PCR products with short 
overlapping sequences, is used to stitch together linear pieces of DNA (16, 17). We 
transform Bacillus subtilis with the linear DNA using the entire Gibson reaction, allowing 
homologous recombination to integrate the gene cluster into the B. subtilis genome (Scheme 
4.1) (18).  
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Successful cloning was confirmed with colony PCR, sequencing, and selection with 
the correct antibiotic resistance.  Proper expression of the peptides was confirmed with liquid 
chromatography mass spectrometry (LCMS) after correct clones were grown, pelleted and 
extracted with methanol.  Additionally, the supernatants are subjected to separation over a 
C18 cartridge. We developed our platform with two well-studied clusters, subtilosin A and 
subtilin, before moving to cryptic clusters.   
 
Scheme 4.1. Strategy for heterologous expression of entire biosynthetic pathways in Bacillus 
subtilis. 
 
4.3 Modifications to Bacillus subtilis host 
To improve the efficiency of our system, we made modifications to our standard host, 
Bacillus subtilis 168.   First, we wanted to engineer an even more competent and 
recombinogenic strain of Bacillus subtilis.  We acquired RM125, which is a version of 
Bacillus subtilis that is restriction modification system deficient (19).  Without the restriction 
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modification system, it will not degrade foreign DNA, thus increasing transformation 
efficiency.  Additionally, we acquired a plasmid for integration of an overexpressed comK 
competence master regulator under control of the PxylA promoter for incorporation at the lacA 
site of Bacillus subtilis (20).  We transformed this into the RM125 strain to make a hyper-
competent Bacillus subtilis strain.  We saw increased transformation efficiency when 65 ng 
of empty plasmid with AmyE homology for the B. subtilis genome is transformed into 
Bacillus subtilis 168 and our modified strains (Figure 4.4). 
 
Figure 4.4. Relative competence of modified Bacillus subtilis hosts.  Each strain was 
transformed with 65 ng of AmyE integration vector pKM003 and selected with 
spectinomycin resistance. 
 
 To further improve our Bacillus subtilis host and further test our cloning strategy, we 
completed a systematic knock-out of Bacillus subtilis natural product biosynthetic gene 
Laboratory 
strain B. 
subtilis 
Restriction modification 
system (hsdR) deficient 
B. subtilis 
Also overexpressing 
competence regulator 
B. subtilis  
Competence 
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clusters (Figure 4.5).  We did this using the same overall cloning strategy described above, 
but also utilizing the Cre/lox system so that we could reuse the same antibiotic resistance 
marker and would not leave multiple resistance markers in the host (21).  This was done in 
both the hyper-competent Bacillus subtilis host and another Bacillus subtilis strain we 
acquired, which was an engineered PY79 strain that had its seven proteases removed.  We 
wanted to utilize the protease-deficient strain, as it has been shown to be a better host for 
protein production (22).  Additionally, we hypothesized that removing the native biosynthetic 
gene clusters would reduce metabolic burden on the cell, and provide a cleaner host 
background.  Furthermore, this would test our Gibson assembly cloning strategy, as most of 
these biosynthetic gene clusters are quite large (over 20 kb).  Previously, a similar approach 
was taken to knock-out the D-amylase gene from Bacillus subtilis (23), but displacing entire 
biosynthetic pathways had never been tested. 
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Figure 4.5. Bacillus subtilis specialized metabolite biosynthetic gene clusters. 
 
 To accomplish the systematic knock-outs, we combined Gibson assembly with the 
Cre/lox system to remove resistance markers (Figure 4.6).  We first amplified 1 kb regions 
of homology directly upstream and downstream from the biosynthetic gene cluster to be 
displaced, along with an zeocin antibiotic resistance marker with flanking loxP sites (21).  
Gibson assembly was used to stitch these pieces together as a linear piece of DNA that can 
be directly transformed into Bacillus subtilis.  Double homologous recombination replaces 
the biosynthetic gene cluster with the zeocin/loxP cassette, which is confirmed by antibiotic 
selection and sequencing.  After obtaining correct clones, a plasmid containing a Cre 
recombinase under control of an IPTG-inducible promoter is transformed into the host (21).  
The Cre recombinase will site-specifically recombine the DNA at the loxP sites, effectively 
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removing the zeocin antibiotic resistance marker (21).  The Cre recombinase in expressed on 
a temperature-sensitive plasmid, so upon incubation at higher temperatures, the plasmid is 
expelled from the Bacillus host and the next round of Gibson assembly can begin (21). This 
method was used to systematically knock-out the surfactin, subtilosin A, plipistatin, 
bacillaene, and bacillibactin biosynthetic gene clusters from both Bacillus subtilis hosts 
(Figure 4.5 and Figure 4.6). 
 
 
Figure 4.6. Strategy for systematic knock-out of Bacillus subtilis specialized metabolite 
biosynthetic gene clusters. 
 
4.4 Heterologous expression of subtilosin A 
We chose the natural product subtilosin A to initially test our strategy for 
heterologous expression of specialized metabolite biosynthetic pathways in Bacillus subtilis. 
Subtilosin A is a good initial cluster as it is natively produced by Bacillus subtilis and is 
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Protease
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already structurally well-characterized (24–26).  Conditions are established for its production 
and isolation and several mutations to its structural gene are  already known to be tolerated 
(27–29).  Subtilosin A is a member of the sactipeptide family of ribosomally-synthesized and 
post-translationally modified peptides (RiPPs), which is characterized by sulfur to D-carbon 
thioether bridges. It is a 35-residue peptide antibiotic, encoded by the structural gene, sboA, 
that is head-to-tail cyclized in addition to three internal thioether bridges that gives it its 
constrained secondary structure (Figure 4.7) (27).  The thioether bonds are catalyzed by the 
radical S-adenosylmethionine (SAM) enzyme, AlbA, from its biosynthetic gene cluster (27). 
 
Figure 4.7. Structure and biosynthetic gene cluster for the sactipeptide antibiotic, subtilosin 
A, from Bacillus subtilis. The sequence of the precursor peptide is listed, with the core region 
in red letters.  The structural gene, sboA, and the radical SAM, albA, are highlighted in the 
pathway as black and red, respectively. 
 
As B. subtilis natively produces subtilosin A, the first step to test our heterologous 
platform on this pathway was to knock-out the entire gene cluster.  Cloning of this 
biosynthetic pathway was done in our hyper-competent Bacillus subtilis host. This was 
accomplished using Gibson assembly to stitch together 1 kb regions of homology to the B. 
Testing Strategy with Known Clusters
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subtilis genome directly upstream and downstream of the cluster with a chloramphenicol 
resistance cassette in between (Figure 4.8).  Homologous recombination replaced the 
subtilosin A biosynthetic gene cluster with the chloramphenicol resistance cassette (Figure 
4.8).  This was verified by PCR, sequencing, and LCMS to confirm lack of compound 
production.  UV analysis showed no absorbance for subtilosin A in the knock-out strain 
(Figure 4.10). 
 
 
Figure 4.8. Strategy to displace the entire subtilosin A biosynthetic pathway with a 
chloramphenicol resistance cassette using Gibson assembly.  Subsequently, the pathway was 
reassembled and replaced. 
 
Next, the majority of the gene cluster (without sboA and albA) was inserted back into 
knock-out strain following the same method of Gibson assembly and transformation that 
utilizes B. subtilis homologous recombination. The final two genes of the cluster (structural 
gene, sboA, and the gene for the radical SAM, albA) were cloned into a Bacillus subtilis 
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integration vector with homology to neutral locus, amyE (Figure 4.9).  This was designed so 
that further modification to the structural gene, sboA, would be feasible without disrupting 
cloning of the entire pathway.  Upon homologous recombination at the amyE site, the entire 
cluster was reassembled only with sboA and albA at a separate site in B. subtilis. Verification 
by LCMS showed production of subtilosin A in our two-piece refactored pathway (Figure 
4.9).  UV analysis showed no absorbance for subtilosin A until both steps of the reassembly 
were complete (Figure 4.10). 
 
 
 
Figure 4.9. Strategy for reassembly of the subtilosin A biosynthetic gene cluster, moving 
sboA and albA to neutral locus, amyE.  We used LCMS to confirm production of the 
rearranged biosynthetic pathway. 
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Figure 4.10.  UV at 220 nm for the various steps of reassembly of the subtilosin A 
biosynthetic gene cluster.  There is no UV peak until after sboA-albA is transformed to 
complete the reassembly. 
 
4.5 Heterologous expression of subtilin 
The next biosynthetic gene cluster that we wanted to express using our heterologous 
platform in Bacillus subtilis is the biosynthetic pathway for the lanthipeptide, subtilin.  
Similar to subtilosin A, subtilin and its pathway are structurally and biosynthetically well-
characterized (30–33). It is produced by a strain of B. subtilis, Bacillus subtilis ATCC 6633, 
although this is a different strain from our heterologous host.  Additionally, one previous 
study has converted B. subtilis 168 into a subtilin producer through transformation of B. 
subtilis 168 with Bacillus subtilis ATCC 6633 genomic DNA, which helped to narrow down 
the size of the biosynthetic machinery necessary for subtilin production (34).  Subtilin is a 
32-residue, class I lanthipeptide antibiotic that contains the characteristic thioether, 
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lanthionine or methyllanthionine bridges (Figure 4.11) (30, 35).  Its pentacyclic structure is 
highly similar to the biopreservative, nisin (Figure 4.11) (30, 31, 35, 36).  Subtilin is 
encoded by the structural gene, spaS, and is modified by the biosynthetic enzymes SpaB and 
SpaC, which install the lanthionine and methyllanthionine bridges through dehydration of 
serine/threonine residues (SpaB) and cyclization onto those residues by cysteine (SpaC) 
(Figure 4.11) (31, 37, 38).  Additionally, the pathway encodes a transporter (SpaT), four 
immunity genes (SpaIEFG), and a two-component regulator (SpaRK) (Figure 4.11) (32, 39–
41). 
 
 
Figure 4.11. Structure and biosynthetic gene cluster for the lanthipeptide antibiotic, subtilin, 
from Bacillus subtilis. The sequence of the precursor peptide is listed, with the core region in 
red letters.  The structural gene, spaS, and the lanthipeptide biosynthesis gene, spaB and 
spaC, are highlighted in the pathway as black and red, respectively. 
 
After initial success with subtilosin A, we modified the same strategy for 
heterologous expression of the biosynthetic gene cluster for subtilin. We used one round of 
Gibson assembly to stitch together the entire cluster, except for the spaS structural gene, 
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along with homology to the Bacillus subtilis genome (Figure 4.12).  The cluster was 
amplified in two pieces, for each half of the cluster before and after the structural gene 
(Figure 4.12).  Using this method, we were able to insert the entire biosynthetic gene cluster 
in the hyper-competent Bacillus subtilis host genome at the location that is homologous to its 
native site.  The structural gene, spaS, has been cloned in a B. subtilis integration plasmid 
containing homology to Bacillus subtilis neutral locus, amyE, making it amenable for 
mutagenesis (Figure 4.12).  Production of subtilin was confirmed by LCMS (Figure 4.12).   
 
 
Figure 4.12. Strategy for reassembly of the subtilin biosynthetic gene cluster, moving spaS 
to neutral locus, amyE.  We used LCMS to confirm production of the heterologously 
expressed biosynthetic pathway. 
 
 Our design for heterologous expression of both the subtilosin A and subtilin 
biosynthetic gene clusters was planned so that modifications to the natural products would be 
easily facilitated.  By moving the structural gene to a site distal from the majority of the 
biosynthetic pathway, mutations could be made to the structural gene (and hence the natural 
product) without effecting the rest of the genes in the gene cluster.  This opens up the 
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possibility of building peptide libraries of RiPPs in Bacillus subtilis (Figure 4.13), which 
could be used to test which mutations are tolerated by the rest of the post-translationally 
modifying enzymes, in addition to testing mutants for improved/modified biological activity.   
 
Figure 4.13. Strategy for building peptide libraries in Bacillus subtilis. 
 
4.6 Unnatural amino acid incorporation in Bacillus subtilis 
In addition to being able to build peptide libraries using the twenty canonical amino 
acids, we wanted to further extend the utility of Bacillus subtilis as a heterologous host 
through incorporation of unnatural amino acids.  Unnatural amino acids could be used for a 
variety of functions including modulating the activity of a natural product by introducing 
new functional groups or providing chemical handles for testing mechanism of action in 
assays (42, 43).  We chose to utilize the amber codon suppression method that involves the 
development of orthogonal tRNA synthetase/tRNA (aaRS/tRNA) pairs to selectively 
incorporate new chemistries at amber stop codons in our peptides of interest (43–47).  This 
system has been widely utilized in E. coli, yeast, and mammalian cells, but has never been 
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reported for Bacillus subtilis (48–51).  Recent work, however, used this system for unnatural 
amino acid incorporation in thiocillin in Bacillus cereus (52).  
The amber codon suppression system works by hijacking a codon (such as the amber 
codon) and assigning it to an orthogonal aaRS/tRNA pair.  First, the tRNA is mutated to 
recognize a codon not usually used for protein expression, such as the amber stop codon.  
The amber codon is the least frequently used stop codon in E. coli and B. subtilis (53).  The 
orthogonal tRNA synthetase is evolved to recognize and acylate its tRNA partner with an 
unnatural amino acid that is externally supplied.  Thus, the unnatural amino acid is able to be 
site-specifically incorporated in a protein that contains the designated codon.  These pairs 
have been identified from archaeal species and modified for expression in E.coli, yeast, and 
mammalian cells (43). To modify this system for use in B. subtilis, changes needed to be 
made for proper expression.  The promoter driving expression of the tRNA synthetase was 
modified to the strong B. subtilis promoter Pspac (Figure 4.14). Additionally, we changed the 
tRNA promoter to a native B. subtilis tRNA promoter (Figure 4.14).  We chose the native B. 
subtilis promoter (rrnD) that drove expression of the group of tRNAs containing the tyrosine 
tRNA, as the first aaRS/tRNA pair we tested (from Methanocaldococcus jannaschii) was a 
tyrosine derivative (50).  Finally, the aaRS/tRNA pair was moved from a B. subtilis 
expression plasmid to integration in neutral locus, lacA, in the B. subtilis genome (Figure 
4.14). This was accomplished by utilizing our Gibson assembly cloning strategy (Scheme 
4.1).  The tRNA promoter/tRNA was purchased as an IDT gblock, and attached to the aaRS, 
along with the Pspac promoter, using overlap PCR.  The lacA homology arms and antibiotic 
resistance marker were added through one Gibson assembly reaction that was transformed 
directly into our hyper-competent Bacillus subtilis host, and integrated into the genome. Our 
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construct for unnatural amino acid incorporation in B. subtilis was then complete (Figure 
4.14). 
 
Figure 4.14. Modifications to E. coli unnatural amino acid incorporation machinery for 
expression in Bacillus subtilis. 
 
To verify unnatural amino acid incorporation in B. subtilis, we used a GFP reporter 
for rapid assessment (Figure 4.15).  We utilized a gfp construct that was mutated with an 
amber codon at the second residue, so that we would only be able to visualize GFP 
fluorescence when we had successful incorporation of our unnatural amino acid.   We 
additionally had to adjust the expression machinery for B. subtilis by adding strong Bacillus 
promoter, Pgrac, and integrating the construct at the neutral amyE locus in the B. subtilis 
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genome containing the orthogonal aaRS/tRNA pair (Figure 4.15).  We could then grow these 
strains with or without the presence of our unnatural amino acid, 4-benzoyl-L-phenylalanine 
(Bpa) at 1mM final concentration.  The Bpa was added when the cultures were at OD = 0.6, 
and then the culture grew seven additional hours for maximum incorporation. The system 
successfully incorporated Bpa in GFP at the amber codon, which was monitored by GFP 
fluorescence over three biological replicates (Figure 4.15).  At peak fluorescence, the 
efficiency is about twelve percent of wild-type GFP under the same conditions (Figure 4.15).   
We next wanted to verify the selectivity of the aaRS/tRNA pair for the designated 
unnatural amino acid.  This was accomplished by purifying GFP by Ni-NTA that was grown 
with or without the presence of the unnatural amino acid and checking the final mass by 
LCMS (Figure 4.15). In our deconvoluted mass spectrum for GFP with Bpa incorporated 
only one new peak appears compared to background when no unnatural amino acid is 
present, indicating we are getting selective incorporation of Bpa (Figure 4.15). This peak is 
within one Dalton of the expected mass (Figure 4.15). 
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Figure 4.15. Successful incorporation of an unnatural amino acid in Bacillus subtilis.  A GFP 
reporter assay coupled to LCMS verified the success and selectivity of unnatural amino acid 
incorporation. 
 
After initial success with incorporation of Bpa in GFP, we wanted to see if we could 
incorporate a different amino acid using other orthogonal aaRS/tRNA pairs that could further 
expand our peptide library capacity.  We chose the pyrrolysyl aaRS/tRNA pair because it has 
been used frequently in the literature, and is promiscuous enough to add chemical handles of 
interest, such as alkenes or alkynes (44).  Additionally, we also chose to test the evolved, 
orthogonal aaRS/tRNA pairs for incorporation of p-cyanophenylalanine (pCNF-RS) and O-
methyltyrosine (MjTyrRS) (54–56). To test these aaRS/tRNA pairs, we first had to perform 
the same cloning steps to change the promoters and integrate the pair in the Bacillus subtilis 
genome, as discussed before with the Bpa aaRS/tRNA pair (Figure 4.14).  We could then 
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test successful incorporation using our GFP reporter as done previously with Bpa (Figure 
4.15 and Figure 4.16). We used boc-L-lysine or O-methyltyrosine as the unnatural amino 
acid to be incorporated for PylRs or pCNF-RS and MjTyrRS, respectively. However, we did 
not achieve the same level of successful incorporation with these aaRS/tRNA pairs, as we 
had with the initial results with Bpa (Figure 4.16). Additionally, we did not see any 
background incorporation of any other endogenous amino acids based on low fluorescence 
intensity (Figure 4.16). 
 
 
Figure 4.16. Testing other orthogonal aaRS/tRNA pairs for unnatural amino acid 
incorporation in Bacillus subtilis.  A GFP reporter assay indicated no incorporation, except 
for the initial test with Bpa.   
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4.7 Summary 
 Developing simplified and robust platforms for the identification of new cryptic gene 
clusters is imperative for the pursuit of new antibiotics.  The untapped potential still available 
in bacterial secondary metabolomes is a rich source for new chemical scaffolds to combat the 
rise of antibiotic resistance.  Using a Bacillus based platform allows for rapid cloning and 
expression of peptides, and circumvents many challenges in the field.  Bacillus is fast-
growing, safe, codon-flexible, highly recombinogenic, and naturally competent.  We 
established a streamlined cloning strategy that uses Gibson assembly to stitch together large 
fragments of DNA (entire biosynthetic pathways in 1-2 pieces) with regions of homology to 
the Bacillus subtilis genome.  This approach allows us to take advantage of the highly 
recombinogenic nature of Bacillus subtilis through direct double homologous recombination 
of the linear DNA product of the Gibson reaction into the genome of B. subtilis upon 
transformation. We can then avoid using plasmids or any other secondary strain during the 
cloning process.   
We wanted to further improve our host, and engineer various Bacillus subtilis strains 
that could be disseminated for general use in heterologous expression. First, we wanted to 
generate a more competent host for more efficient transformation of large assemblies of 
DNA.  To do this, we obtained a strain of B. subtilis that was restriction modification system 
deficient and a plasmid that overexpression B. subtilis master competence regulator, ComK.  
We then combined both, integrating the overexpressed ComK in the neutral lacA locus of the 
hyper-competent Bacillus subtilis.  Next, to reduce metabolic burden on the host, provide a 
cleaner background for characterization, and test our cloning strategy, we did a systematic 
knock-out of specialized metabolite natural product pathways from the hyper-competent and 
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a protease-deficient Bacillus subtilis hosts.  We combined our Gibson assembly strategy with 
the Cre/lox system to knock-out the biosynthetic pathways and subsequently remove any 
selection markers.   
Having our B. subtilis hosts in hand, we used our cloning strategy to rearrange and 
heterologously express two Bacillus natural products. These were known natural products 
from two different families of RiPPs biosynthetic pathways.  We designed our strategy so 
that we moved the structural gene to a different, neutral site in the B. subtilis genome to 
facilitate subsequent mutations to the natural product.  To be able to further expand the 
capabilities of our heterologous platform, we wanted to be able to incorporate unnatural 
amino acids in natural product peptides in Bacillus subtilis.  These could affect biological 
activity by adding new chemical functionalities or be useful handles for various assays.  We 
were successfully able to incorporate the unnatural amino acid benzoyl-L-phenylalanine into 
GFP in Bacillus subtilis. We have developed tools that will enable future efforts to discover, 
characterize, and modify natural product antibiotics in Bacillus subtilis. 
 
4.8 Experimental 
4.8.1 General Methods 
Mass spectrometry measurements were recorded using an Agilent 6520 Accurate-
Mass Q-TOF ESI positive in high-resolution mode. All materials required for cloning 
(enzymes, reagents, Gibson Master Mix) were purchased from New England Biosciences 
(NEB) unless otherwise stated. One-Shot® Top10 cells were purchased from InvitrogenTM 
(ThermoFisher Scientific). Bacillus strains and plasmids were acquired from the Bacillus 
Genome Stock Center (BGSC). RM125 was acquired from Kenji Tsuge at the Institute for 
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Advanced Biosciences, Keio University.  pKM003 was acquired from Elizabeth Shank at 
UNC. GeneJET Plasmid Miniprep kit was purchased from ThermoFisher Scientific. C18 
cartridges were purchased form Waters Corporation.  All aaRS/tRNA pairs for unnatural 
amino acid incorporation (MjTyrRS, pCNF-RS, PylRS) were acquired from the Brustad Lab 
at UNC. Unnatural amino acids 4-benzoyl-L-phenylalanine (Bpa), boc-L-lysine, and O-
methyl-L-tyrosine were purchased from Chem-Impex Int’l Inc. All other solvents and 
reagents were purchased from Fisher Scientific and used as received unless otherwise noted.  
 
4.8.2 Strains and Plasmids 
Strains were maintained in Luria–Bertani (LB)-Miller (10 g tryptone, 5 g yeast 
extract and 10 g NaCl per liter) media unless otherwise noted.  Plasmids were maintained in 
One-Shot® Top10 DH5D cells and grow in LB with appropriate antibiotic unless otherwise 
noted.  All plasmids and strains used in this study are listed in Table 4.1 and Table 4.2, 
respectively. 
 
 
Plasmid Other name Description
pAX01-comK BGSC ECE222 pAX01 with PxylA-comK and lacA homology
pKM003 amyE integration vector SpR
p7Z6 BGSC ECE203 pMD18-T containing lox71-zeo-lox66 cassette
pTSC BGSC ECE204 pTS (temperature sensitive) containing Pspac-creexpression cassette 
pBs1C BGSC ECE257 amyE integration vector CmR
pBs2E BGSC ECE258 lacA integration vector EmR
pEVOL-pBpF aaRS/tRNA for Bpa  incorporation
pUltra-PylRS PylRS/PylT pair
pUltra-MjTyrRS O-Me-TyrRS/tRNA
pUltra-CNF pCNF aaRS/tRNA
pDG148 Pspac-containing expression vector
Plasmid Other name Description
pAX01-comK BGSC ECE222 pAX01 with PxylA-comK and lacA homology
pKM003 amyE integration vector SpR
p7Z6 BGSC ECE203 pMD18-T containing lox71-zeo-lox66 cassette
pTSC BGSC ECE204 pTS (temperature sensitive) containing Pspac-creexpression cassette 
pBs1C BGSC ECE257 amyE integration vector CmR
pBs2E BGSC ECE258 lacA integration vector EmR
pEVOL-pBpF aaRS/tRNA for Bpa  incorporation
pUltra-PylRS PylRS/PylT pair
pUltra-MjTyrRS O-Me-TyrRS/tRNA
pUltra-CNF pCNF aaRS/tRNA
pDG148 Pspac-containing expression vector
pEVOL-gfp2tag GFP2TAG-containing vector
pEVOL-gfp WT GFP WT containing vector
pHT01 Pgrac-containing expression vector
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Table 4.1. Plasmids used in this study. 
 
Table 4.2. Strains used in this study. 
 
4.8.3 Gibson assembly for Bacillus subtilis 
The protocol for Gibson assembly in Bacillus subtilis was modified from the 
established method (16, 17).  The first step is to design primers for proper assembly, which 
Strain Other name Description
Bacillus subtilis 168 WT
Bacillus subtilis RM125 arg(GH)15 hsd(I)R-M- leuB8 SP10(S)
Bacillus subtilis RM125K RM125 lacA::PxylA-comK
Bacillus subtilis KO7 BGSC 1A1133 PY79 ΔnprE ΔaprE Δepr Δmpr ΔnprB Δvpr Δbpr
Bacillus subtilis KO7 KO5 KO7 Δ5BGCs
Bacillus subtilis KO7 1 KO7 Δbacillibactin BGC
Bacillus subtilis KO7 2 KO7 Δbacillaene BGC
Bacillus subtilis KO7 3 KO7 Δplipistatin BGC
Bacillus subtilis KO7 4 KO7 Δsurfactin BGC
Bacillus subtilis KO7 5 KO7 Δsubtilosin A BGC
Bacillus subtilis KO7 1/2 KO7 Δbacillibactin/bacillaene BGCs
Bacillus subtilis KO7 1/2/3 KO7 Δbacillibactin/bacillaene/plipistatin BGCs
Bacillus subtilis KO7 1/2/3/4 KO7 Δbacillibactin/bacillaene/plipistatin/surfactin BGCs
Bacillus subtilis RM125 KO5 RM125 Δ5BGCs
Bacillus subtilis RM125 KO5 1 RM125 Δsurfactin BGC
Bacillus subtilis RM125 KO5 2 RM125 Δplipistatin BGC
Bacillus subtilis RM125 KO5 3 RM125 Δbacillibactin BGC
Bacillus subtilis RM125 KO5 4 RM125 Δbacillaene BGC
Bacillus subtilis RM125 KO5 5 RM125 Δsubtilosin A BGC
Bacillus subtilis RM125 KO5 1/2 RM125 Δsurfactin/plipistatin BGCs
Bacillus subtilis RM125 KO5 1/2/3 RM125 Δsurfactin/plipistatin/bacillibactin BGCs
Bacillus subtilis RM125 KO5 1/2/3/4 RM125 Δsurfactin/plipistatin/bacillibactin/bacillaene BGCs
Bacillus subtilis RM125 AKO RM125 subtilosin A BGC::chlor
Bacillus subtilis RM125 AKI 1 RM125 subtilosin A BGC Knock-In part 1 (no sboA-albA)
Bacillus subtilis RM125 AKI 2 RM125 subtilosin A BGC Knock-In part 2  amyE::sboA-albA
Bacillus subtilis RM125 SKI 1 RM125 subtilin BGC Knock-In part 1 (no spaS)
Bacillus subtilis RM125 SKI 2 RM125 subtilin BGC Knock-In part 2  amyE::spaS
Bacillus subtilis RM125 Bpa RM125 lacA::MjaaRS/tRNA
Bacillus subtilis RM125 BpaGW RM125 lacA::MjaaRS/tRNA amyE::gfp
Bacillus subtilis RM125 BpaGT RM125 lacA::MjaaRS/tRNA amyE::gfp2tag
Bacillus subtilis RM125 Pyl RM125 lacA::pylRS/tRNA
Bacillus subtilis RM125 PylGT RM125 lacA::pylRS/tRNA amyE::gfp2tag
Bacillus subtilis RM125 CNF RM125 lacA::pCNFRS/tRNA
Bacillus subtilis RM125 CNFGT RM125 lacA::pCNFRS/tRNA amyE::gfp2tag
Bacillus subtilis RM125 OMT RM125 lacA::MjTyrRS/tRNA
Bacillus subtilis RM125 OMTGT RM125 lacA::MjTyrRS/tRNA amyE::gfp2tag
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contained 20-30 bp of annealing portion for the gene or DNA being amplified with an 
additional 30 bp of homology to the piece that going to be attached (Table 4.5 - Table 4.8).  
Otherwise followed standard guidelines for melting temperature and GC content. Next, 
amplify DNA by PCR using Phusion® High-Fidelity Polymerase with HF-buffer following 
the manufacturer’s manual or Q5® High-Fidelity Polymerase with Q5 Reaction Buffer 
following the manufacturer’s manual.  The purified PCR products are directly used in the 
Gibson assembly reaction using the 2X Gibson Assembly® Master Mix from NEB.  When 
necessary, digest plasmid using restriction endonucleases (different combinations of SpeI, 
PstI, NdeI) from NEB following the manufacturer’s manual.  The purified digest can also be 
used directly in the Gibson assembly reaction.  To set up the Gibson assembly reaction, add 
0.1 pmol (or more if indicated) of each piece of DNA to be assembled along with 10 µL of 
2X thawed NEB Gibson Assembly Master Mix, and fill to 20 µL total volume with nuclease-
free water.  The reaction is set up on ice, and then incubated at 50 oC for 60 minutes before 
being placed on ice again until ready to transform.  Transform the entire reaction into 1 mL 
of competent Bacillus subtilis cells following standard protocol (4.8.4 Transformation of 
Bacillus subtilis). 
 
4.8.4 Transformation of Bacillus subtilis 
Transformation followed established protocol (57).  First, all components of the 
Bacillus subtilis transformation media need to prepared.  The 10X S-base (Table 4.3) is 
mixed and autoclaved before addition of MgSO4.  
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Table 4.3. Composition of 10X S-base for B. subtilis transformations. 
 
The 10X S-base is then added with the rest of the components to make the HS and LS 
media (Table 4.4).  Each component of the HS and LS media is either autoclaved or sterile 
filtered through a 0.22 µm filter.  Once they are all combine, one final filtration is completed 
through a 0.22 µm filter. 
 
 
Table 4.4. Composition of HS and LS media for B. subtilis transformations. 
 
10X S-base
2 g (NH4)2SO4
14 g K2HPO4
6 g KH2PO4
1 g sodium citrate
Distilled water to 100 mL
0.1 mL 1M MgSO4 after autoclaving
HS Media LS Media
56.3 mL distilled water 83.8 mL distilled water
10 mL 10X S-base 10 mL 10X S-base
2.5 mL 20% (w/v) glucose 2.5 mL 20% (w/v) glucose
5 mL 0.1% (w/v) L-tryptophan 0.5 mL 0.1% (w/v) L-tryptophan
1 mL 2% (w/v) casein 0.5 mL 2% (w/v) casein
5 mL 10% (w/v) yeast extract 1 mL 10% (w/v) yeast extract
10 mL 8% (w/v) arginine, 0.4% histidine 0.25 mL 1M MgCl2
10 mL 0.5mg/ml uracil 0.05 mL 1M CaCl2
200 µL MgSO4 1 mL 0.5mg/ml uracil
200 µL MgSO4
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To transform, first grow a 5 mL culture of the B. subtilis recipient strain overnight at 
37 oC in HS media.  Then inoculate 20 mL of LS media with 1 mL of overnight HS culture, 
and incubate about 4 hrs at 30 oC (until OD about 1.5 or cells are in early stationary phase). 
Transfer 1 ml of LS culture to an Eppendorf tube or culture tube, and add 10 µL of 0.1 M 
EGTA (adjusted to pH 7.2 using 10 M NaOH and sterile filtered using a 0.22 µm filter).  Let 
the cells sit at room temperature for 5 mins.  Add 1-2 µg of DNA or all of the Gibson 
Assembly reaction, and recover the cells for 2 hrs at 37 oC.  If recovering in an Eppendorf 
tube, shake it horizontally in an Erlenmeyer flask to increase oxygen surface area.  Plate all 
cells on an LB agar plate with appropriate antibiotic selection.  Incubate the plate at 37 oC 
overnight. 
 
4.8.5 Cloning Knock-outs with Cre/lox System 
The regions of homology directly upstream and downstream of each biosynthetic 
gene cluster were amplified from B. subtilis 168 genomic DNA by PCR using Q5® High-
Fidelity Polymerase with Q5 Reaction Buffer following the manufacturer’s manual. Primers 
P3-P6 were used for the subtilosin A knock-out, P7-12 were used for the surfactin cluster, 
P13-16 were used for the plipistatin cluster, P17-P20 were used for the bacillibactin cluster, 
and P21-24 were used for the bacillaene cluster (Table 4.5). The lox-zeo-lox cassette was 
amplified using primers P1-2 (Table 4.5) from the P7Z6 plasmid (Table 4.1) by PCR using 
Q5® High-Fidelity Polymerase with Q5 Reaction Buffer following the manufacturer’s 
manual.  The gel-purified PCR products were assembled using the Gibson assembly protocol 
(4.8.3 Gibson assembly for Bacillus subtilis) and transformed directly into Bacillus subtilis 
(4.8.4 Transformation of Bacillus subtilis).  Colonies were selected on LB-agar plates 
 130 
containing zeocin (20 Pg/mL).  Colony PCR was done to confirm proper knock-out using the 
upstream F and downstream R primers (Table 4.5).  Positive clones were transformed with 
plasmid pTSC (Table 4.1) containing the Cre recombinase following the B. subtilis 
transformation protocol (4.8.4 Transformation of Bacillus subtilis). Colonies were selected 
on LB-agar plates containing erythromycin (3 Pg/mL).  Colony PCR was done to confirm 
loss of zeocin using the upstream F and downstream R primers (Table 4.5).  Positive clones 
were restruck on LB-agar plates with no antibiotic and incubated at 37 oC. Colonies were 
then restruck on LB-agar containing erythromycin to verify the pTSC plasmid had been lost. 
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Table 4.5. Primers used in this study for biosynthetic pathway knock-outs. 
 
4.8.6 Cloning subtilosin A  
To first knock-out the subtilosin A biosynthetic gene cluster, the regions of homology 
directly upstream and downstream of the pathway were amplified from B. subtilis 168 
genomic DNA by PCR using Q5® High-Fidelity Polymerase with Q5 Reaction Buffer 
Primer Description Sequence 5'-3'
P1 lox-zeo-lox cassette F GAGCTCGGTACCCGGGGATCCTCTA
P2 lox-zeo-lox cassette R GCTTGCATGCCTGCAGGTCGACGAT
P3 subtilosin up homology F CTGCTTCCAGTACAGACGGAATCAGCTTTGTTAAAT
P4 subtilosin up homology R Gib lox cassette
ATCTCTAGAGGATCCCCGGGTACCGAGCTCAATTGA
ATCCTCCCTTTTTTTGTTTTTCTAGCAGATC 
P5 subtilosin down F Gib lox cassette GTAGAATCGTCGACCTGCAGGCATGCAAGCAATAGCTACATCGCAATCGCAGACG
P6 subtilosin down homology R GATTCATACTGAAGAGATTGATCAAGTTG
P7 surfactin up homology F AAAGAATTTTAGTTCCTAGCTTCATCTTAAATCG
P8 surfactin up homology R Gib comS ATGCTTGCCTGATCGGTTCATACGTCTGCTCCTCCCCTAATCTTTATAAGCAGTGAAC
P9 comS F Gib Surfactin up homologyATGTTCACTGCTTATAAAGATTAGGGGAGGAGCAGACGTATGAACCGATCAGG
P10 comS  R Gib lox cassette ATCTCTAGAGGATCCCCGGGTACCGAGCTCCGTTTTCAAGCCGGTCTTTAT 
P11 surfactin down homology F Gib lox cassette
GTAGAATCGTCGACCTGCAGGCATGCAAGCTCAAA
AGCGGACAGCTTCGGCTGTT 
P12 surfactin down homology R GAATAACAGGATAAACCCGAAGTACC
P13 plipistatin up homology F CAAGGTATTACTGTGAAAGGGGACA
P14 plipistatin up homology R Gib lox cassette
ATCTCTAGAGGATCCCCGGGTACCGAGCTCCGGATT
CCCTCCAGTTCTCATAATA
P15 plipistatin down homology F Gib lox cassette
GTAGAATCGTCGACCTGCAGGCATGCAAGCAGCGG
ATTAGCGGACAGAGGCCATT 
P16 plipistatin down homology R GGGTTTCTTCAATCATAAATGCAAGAGG
P17 bacillibactin up homology F GTACGGAAGTGCGTATGATGTCTTC 
P18 bacillibactin up homology R Gib lox cassette
ATCTCTAGAGGATCCCCGGGTACCGAGCTCATCATC
AATTCCTTTCTTCGCTCTA
P19 bacillibactin down homology F Gib lox cassette
GTAGAATCGTCGACCTGCAGGCATGCAAGCGGGAG
GAGAAATAGAATGGCAAATC
P20 bacillibactin down homology R GAGACCATTTCACGAATTATGACTATGAAG
P21 bacillaene up homology F GGAAGCGTATGTGATGCCAAGTATG 
P22 bacillaene up homology R Gib lox cassette
ATCTCTAGAGGATCCCCGGGTACCGAGCTCAGCTTT
ATTGTAACAAGAAAAAAATGAGAGGGCA
P23 bacillaene down homology F Gib lox cassette
GTAGAATCGTCGACCTGCAGGCATGCAAGCTTGCAT
TCTCCTCGCCTAATAGGGT
P24 bacillaene down homology R GGGAAACGCTCAATATGAAGCCGGG
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following the manufacturer’s manual. Primers P3, P25, P28, and P6 were used for the 
subtilosin A knock-out, (Table 4.6). The chlor antibiotic resistance marker was amplified 
using primers P26-27 (Table 4.6) from the pBS1C (58) plasmid (Table 4.1) by PCR using 
Q5® High-Fidelity Master Mix with Q5 Reaction Buffer following the manufacturer’s 
manual.  The gel-purified PCR products were assembled using the Gibson assembly protocol 
(4.8.3 Gibson assembly for Bacillus subtilis) and transformed directly into Bacillus subtilis 
(4.8.4 Transformation of Bacillus subtilis).  Colonies were selected on LB-agar plates 
containing chloramphenicol (5 Pg/mL).  Colony PCR was done to confirm proper knock-out 
using the upstream F and downstream R primers (Table 4.5).  Additionally, LCMS was used 
to confirm that subtilosin A was not being produced.  
To reinsert the subtilosin A biosynthetic gene cluster, the regions of homology 
directly upstream and downstream of the pathway along with the gene cluster (without sboA-
albA) were amplified from B. subtilis 168 genomic DNA by PCR using Q5® High-Fidelity 
Master Mix with Q5 Reaction Buffer following the manufacturer’s manual. Primers P3, P29, 
P32, P33, P34, and P6 were used to accomplish this (Table 4.5 and Table 4.6). The spec 
antibiotic resistance marker was amplified using primers P30-31 (Table 4.6) from the 
pKM003 plasmid (Table 4.1) by PCR using Q5® High-Fidelity Polymerase with Q5 
Reaction Buffer following the manufacturer’s manual.  The gel-purified PCR products were 
assembled using the Gibson assembly protocol (4.8.3 Gibson assembly for Bacillus subtilis) 
and transformed directly into Bacillus subtilis (4.8.4 Transformation of Bacillus subtilis).  
Colonies were selected on LB-agar plates containing spectinomycin (100 Pg/mL).  
To complete the subtilosin A biosynthetic gene cluster, the sboA-albA genes were 
amplified from B. subtilis 168 genomic DNA by PCR using Q5® High-Fidelity Polymerase 
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with Q5 Reaction Buffer following the manufacturer’s manual. Primers P35 and P36 were 
used to accomplish this (Table 4.6).  The purified PCR product and the pBs1C plasmid (58) 
(Table 4.1) were digested using SpeI. The purified digested plasmid was treated with 
Antarctic Phosphatase (AP) according to the manufacturer’s manual, and then combined with 
the purified, digested PCR product in the presence of T4 ligase. The ligation was allowed to 
go overnight at 16 oC according to the manufacturer’s manual. After ligation, the T4 ligase 
was heat inactivated at 65 oC for 10 min before being transformed into One-Shot ® Top 10 
cells according to the manufacturer’s manual. Colonies were select on LB-agar plates 
containing ampicillin (100 Pg/mL). The plasmid was harvested from cells by GeneJET 
Plasmid Miniprep kit and sequenced. Correct clones were confirmed by LCMS for 
production of subtilosin A (Figure 4.8). 
 
 
Primer Description Sequence 5'-3'
P25 subtilosin up homology R Gib chlor
CTGTCAAACATGAGAATTGACACAATTGAATCCTCCCTT
TTTTTGTTTTTCTAGCAGATC 
P26 chlor F Gib subtilosin up homology
TAGAAAAACAAAAAAAGGGAGGATTCAATTGTGTCAAT
TCTCATGTTTGACAGCTTATCATC
P27 chlor R Gib subtilosin down homology
GGGTCCGTCTGCGATTGCGATGTAGCTATTTTATAAAAG
CCAGTCATTAGGCCTATCTG
P28 subtilosin down homology F Gib chlor
TCAGATAGGCCTAATGACTGGCTTTTATAAAATAGCTAC
ATCGCAATCGCAGACG
P29 subtilosin up homology R Gib spec AATTGAATCCTCCCTTTTTTTGTTTTTCTAGCAGATC
P30 spec F Gib subtilosin up homology
TAGAAAAACAAAAAAAGGGAGGATTCAATTAACGTAAC
GTGACTGGCAAG
P31 spec R Gib subtilosin cluster TTTGTGCTGGTGACAAATCGTTTCCCTCCTATGCAAGGGTTTATTGTTTTCTAAAATCTG
P32 subtilosin cluster F GATTTTAGAAAACAATAAACCCTTGCATAGGAGGGAAACGATTTGTCACCAGCAC 
P33 subtilosin cluster R GGGTCCGTCTGCGATTGCGATGTAGCTATTTTATAGATCAAGAGAAGCGGTGCTG
P34 subtilosin down homology F Gib cluster
TATCACAGCACCGCTTCTCTTGATCTATAAAATAGCTACA
TCGCAATCGCAGACG
P35 sboA-albA F SpeI GATCGATCACTAGTCATTCGGTTTGTAAACTTCAACTGC
P36 sboA-albA R SpeI GATCGATCACTAGTCTAAATAAGCTGGACCACGTCTTCTAATTGTTC 
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Table 4.6. Primers used in this study for subtilosin A heterologous expression. 
 
4.8.7 Cloning subtilin 
To clone the majority of the subtilin biosynthetic gene cluster, the regions of 
homology directly upstream and downstream of the pathway were amplified from B. subtilis 
168 genomic DNA and the gene cluster (without spaS) was amplified from B. subtilis ATCC 
6633 by PCR using Q5® High-Fidelity Polymerase with Q5 Reaction Buffer following the 
manufacturer’s manual. Primers P37-P38 and P41-46 were used to accomplish this (Table 
4.7). The spec antibiotic resistance marker was amplified using primers P39-40 (Table 4.7) 
from the pKM003 plasmid (Table 4.1) by PCR using Q5® High-Fidelity Polymerase with 
Q5 Reaction Buffer following the manufacturer’s manual.  The gel-purified PCR products 
were assembled using the Gibson assembly protocol (4.8.3 Gibson assembly for Bacillus 
subtilis) and transformed directly into Bacillus subtilis (4.8.4 Transformation of Bacillus 
subtilis).  Colonies were selected on LB-agar plates containing spectinomycin (100 Pg/mL).  
To complete the subtilin biosynthetic gene cluster, the spaS gene was amplified from 
B. subtilis ATCC 6633 genomic DNA by PCR using Q5® High-Fidelity Master Mix with Q5 
Reaction Buffer following the manufacturer’s manual. Primers P47 and P48 were used to 
accomplish this (Table 4.7).  The purified PCR product and the pBs1C plasmid (58) (Table 
4.1) were digested using SpeI. The purified digested plasmid was treated with Antarctic 
Phosphatase (AP) according to the manufacturer’s manual, and then combined with the 
purified, digested PCR product in the presence of T4 ligase. The ligation was allowed to go 
overnight at 16 oC according to the manufacturer’s manual. After ligation, the T4 ligase was 
heat inactivated at 65 oC for 10 min before being transformed into One-Shot ® Top 10 cells 
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according to the manufacturer’s manual. Colonies were select on LB-agar plates containing 
ampicillin (100 Pg/mL). The plasmid was harvested from cells by GeneJET Plasmid 
Miniprep kit and sequenced. Correct clones were confirmed by LCMS for production of 
subtilosin A (Figure 4.10). 
 
 
Table 4.7. Primers used in this study for subtilin heterologous expression. 
 
4.8.8 Cloning for Unnatural Amino Acid Incorporation 
To clone aaRS/tRNA pairs for expression in B. subtilis, the aaRS was amplified from 
the corresponding plasmid (Table 4.1) by PCR using Q5® High-Fidelity Polymerase with 
Q5 Reaction Buffer following the manufacturer’s manual. Primers P51-P52 and P56-57 were 
used to accomplish this (Table 4.8). The Pspac promoter was amplified using primers P49-50 
or 55 (Table 4.8) from the pDG148 plasmid (Table 4.1) by PCR using Q5® High-Fidelity 
Primer Description Sequence 5'-3'
P37 subtilin up homology F AACTCAAAAGACGAGCTGGGTGATCTGAA
P38 subtilin up homology R TTAAATCGTAAACTGACCCATCTTCTCATTAAG
P39 spec F Gib subtilin up homology AATGAGAAGATGGGTCAGTTTACGATTTAAAGTGTTTCCACCATTTTTTCAATTTTTTTA 
P40 spec R AACGTAACGTGACTGGCAAG
P41 subtilin cluster F Gib spec AAAAATATCTCTTGCCAGTCACGTTACGTTCTGTCATTATGGCAGGCTTGC
P42 subtilin cluster P1 R Gib P2 CAAGGTGATGCTAATGGTTTTACTTAAATTAATAATGCTTTTGTCCAATCTGT 
P43 subtilin cluster P2 F Gib P1 ACAGATTGGACAAAAGCATTATTAATTTAAGTAAAACCATTAGCATCACCTTGCTCTGAC
P44 subtilin cluster P2 R Gib down homology
GGGGCGAAACATGTTCAATCAGCTGCATAGTTA
TTCGTTTCTTAAAGGTATTTTTACTCG
P45 subtilin down homology F CTATGCAGCTGATTGAACATGTTTCGC
P46 subtilin down homology R ATGAACGTGCTTGAACAGTTAATGACG
P47 spaS F SpeI GATCGATCACTAGTAAGGAAAAAAATGATAAAATCTTGATATTTGTCTGTTAC
P48 spaS R SpeI GATCGATCACTAGTGTGCAAGGAGTCAGAGCAAGGTGAT 
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Polymerase with Q5 Reaction Buffer following the manufacturer’s manual.  The rrnD-tRNA 
DNA was amplified from the corresponding gblock purchased from Integrated DNA 
Technologies (IDT) (Bpa and PylT) or from the corresponding plasmid (OMeTyr and pCNF) 
(Table 4.1) by PCR using Q5® High-Fidelity Polymerase with Q5 Reaction Buffer 
following the manufacturer’s manual.  Primers P53-P54 or P58 and P60-61 were used to 
accomplish this (Table 4.8).  The rrnD promoter was amplified from a gblock purchased 
from Integrated DNA Technologies (IDT) by PCR using Q5® High-Fidelity Polymerase 
with Q5 Reaction Buffer following the manufacturer’s manual.  Primers P53 and P59 were 
used to accomplish this (Table 4.8). The gel-purified PCR products were assembled using 
overlap PCR for promoter/aaRS/rrnD/tRNA using the overlap PCR protocol (4.8.9 Overlap 
PCR).  The pBS2E plasmid (58) (Table 4.1) was digested using SpeI, PstI, and NdeI with 
buffer 10X NEB 2.1 according the manufacturer’s manual. The gel-purified overlap PCR 
products and purified, digested pBS2E were assembled using the Gibson assembly protocol 
(4.8.3 Gibson assembly for Bacillus subtilis) and transformed directly into Bacillus subtilis 
(4.8.4 Transformation of Bacillus subtilis).  Colonies were selected on LB-agar plates 
containing erythromycin (3 Pg/mL) and confirmed by colony PCR and sequencing.  
 
gblock rrnD-tRNA BpF: 
CCTGCTGACTTTCTCGCCGATCAAATATTTTTGAATGATGTCACACCTGTTATCTA
GTTTTGAGAGAATAAGTTTTTCAAAAAAACACTTGATTTTCTCAAGAATACATAG
TATAATGTTAAATGTCACTGAAATTGCCCGCCCTAGTTCAGAGGCAGAACG 
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gblock rrnD-PylT: 
GCCTGCTGACTTTCTCGCCGATCAAAAAAAAAACATTTGACAAAAGAAAGTCAA
AATGTTATATTAATAAAGTCGCTTCAACAAGAAGTGGAAACCTGATCATGTAGA
TCGAATGGACTCTAAATCCGTTCAGCCGGGTTAGATTCCCGGGGTTTCCGCCAGA
AAAGGAGCCTCGGCTCCTTTTTATACTTACTCGCATGCTCGAGCAGCTCAGGGTC
GAAT 
 
To clone the GFP reporter for unnatural amino acid incorporation, gfp2tag or gfp wt 
was amplified from the corresponding plasmid (Table 4.1) by PCR using Q5® High-Fidelity 
Polymerase with Q5 Reaction Buffer following the manufacturer’s manual. Primers P66-P68 
were used to accomplish this (Table 4.8). The Pgrac promoter was amplified using primers 
P62-P63 (Table 4.8) from the pHT01 plasmid (Table 4.1) by PCR using Q5® High-Fidelity 
Master Mix with Q5 Reaction Buffer following the manufacturer’s manual.  The pKM003 
plasmid (Table 4.1) was digested using HindIII according the manufacturer’s manual. The 
gel-purified Pgrac promoter PCR products and purified, digested pKM003 were assembled 
using the In-Fusion® HD cloning kit according to the manufacturer’s manual, and 
transformed into One-Shot ® Top 10 cells according to the manufacturer’s manual. Colonies 
were select on LB-agar plates containing ampicillin (100 Pg/mL). The plasmid was harvested 
from cells by GeneJET Plasmid Miniprep kit and sequenced.  The Pgrac-pKM003 plasmid 
was amplified using primers P64-P65 (Table 4.8) by PCR using Q5® High-Fidelity 
Polymerase with Q5 Reaction Buffer following the manufacturer’s manual. The gel-purified 
PCR products (gfp and Pgrac-pKM003) were assembled using the Gibson Assembly Master 
Mix according to the manufacturer’s manual and transformed into One-Shot ® Top 10 cells 
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according to the manufacturer’s manual. Colonies were select on LB-agar plates containing 
ampicillin (100 Pg/mL). The plasmid was harvested from cells by GeneJET Plasmid 
Miniprep kit and sequenced.  The Pgrac-gfp pKM003 plasmid was transformed into Bacillus 
subtilis containing the aaRS/tRNA pairs (4.8.4 Transformation of Bacillus subtilis).  
Colonies were selected on LB-agar plates containing spectinomycin (100 Pg/mL) and 
confirmed by colony PCR and sequencing. 
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Table 4.8. Primers used in this study for unnatural amino acid incorporation. 
 
4.8.9 Overlap PCR 
For overlap PCR for the aaRS/tRNA cloning, set up a standard PCR reaction using 
Gibson primers for the individual pieces that need to be assembled using Q5® High-Fidelity 
Master Mix with Q5 Reaction Buffer following the manufacturer’s manual.  The gel-purified 
Primer Description Sequence 5'-3'
P49 Pspac F Gib pBs2E TGGAATTCGCGGCCGCTTCTAGAGCATATAGAATTCTACACAGCCCAG
P50 Pspac R Gib aaRS TTCAAATTCGTCCATTCTAGATCACCTCCTTAAGC
P51 aaRS F Gib Pspac AGGAGGTGATCTAGAATGGACGAATTTGAAATGATAAAG
P52 aaRS R Gib gblock tRNA TTTGATCGGCGAGAAAGTCAGCAGGCCGCTTAGTTAGCCGTGCACTGATCA
P53 gblock tRNA F Gib aaRS CGATATGATCAGTGCACGGCTAACTAAGCGGCCTGCTGACTTTCTCGCCGATCAAA 
P54 gblock tRNA R Gib pBS2E CAAATATAGCTTGAAATCGATATCTCTGCAATTCGACCCTGAGCTGCTCGAGCAT
P55 Pspac R Gib pylRS ATCAGAGTGTTTAGTGGTTTTTTATCCATTCTAGATCACCTCCTTAAGC 
P56 pylRS F Gib Pspac AGGAGGTGATCTAGAATGGATAAAAAACCACTAAACACTCTGA
P57 pylRS R Gib pBS2E TTTGATCGGCGAGAAAGTCAGCAGGCTTACAGGTTGGTAGAAATCCCGTTA
P58 gblock tRNA F Gib pylRS TACTATAACGGGATTTCTACCAACCTGTAAGCCTGCTGACTTTCTCGCCGATCAAA
P59 rrnD R overlap OMeYtRNA
CGTTCTGCCCTGCTGAACTACCGCCGGACTTCTTGTTGAAG
CGACTTTATTAATATAAC
P60 OMeYtRNA F overlap rrnD TTATATTAATAAAGTCGCTTCAACAAGAAGTCCGGCGGTAGTTCAGCAGGGCAG
P61 OMeYtRNA R terminator CCTGAGCTGCTCGAGCATGCGAGTAAGTATAAAAAGGAGCCGAGGCTCCTTTTCTGGTCCGGCGGGCCGGATTTGAA
P62 Pgrac F Infusion pKM003 TTCAGAATGTTGCTAAGCTAGCTATTGTAACATAATCGGTAC
P63 Pgrac R Infusion pKM003 GTTCCTCCTTATGTAAGCTTTCCTCCTTTAATTGGGAATTGTTATCCGC
P64 Pgrac R Gib gfp AAGCTTTCCTCCTTTAATTGGGAATTGTTATCCGCTCAC
P65 pKM003 F Gib gfp TAAGGATCCTGAGCGCCGGTCGCTA
P66 gfp2tag F Gib Pgrac GCGGATAACAATTCCCAATTAAAGGAGGAAAGCTTATGTAGAAAGGAGAAGAACTTTTC
P67 gfp R Gib pKM003 CTGGTAATGGTAGCGACCGGCGCTCAGGATCCTTATTAGTGATGGTGATGGTGATG
P68 gfp-wt F Gib Pgrac GCGGATAACAATTCCCAATTAAAGGAGGAAAGCTTATGTCGAAAGGAGAAGAACTTTTC
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PCR products to be assembled are then combined in a new PCR reaction containing primers 
for the ends of the final overlap PCR product.  Primers P49 and P54 were used to accomplish 
this for the Pspac/aaRS/rrnD/tRNA overlap (Table 4.8).  The PCR cycle has an initial extra 
ten cycles at a lower annealing temperature to help the pieces of the template anneal (Table 
4.9).  Extension time and annealing temperature can be adjusted as for a regular PCR. 
 
Cycle Step Temperature (oC) Time Cycles 
Initial 
Denaturing 98 30 sec 1 
Denaturing 98 10 sec  
Annealing  50 20 sec 10 
Extension 72 30 sec  
Denaturing 98 10 sec 
 Annealing  62 to 52 20 sec 20 
Extension 72 30 sec 
 Denaturing 98 10 sec 
 Annealing   52 20 sec 20 
Extension 72 30 sec 
 Final 
Extension 72 8 min  1 
Hold 4 
   
Table 4.9. Overlap PCR cycling. 
 
4.8.10 Colony PCR 
For colony PCR of Bacillus subtilis colonies, first lyse the cells and then set up a 
standard PCR reaction using Q5® High-Fidelity Polymerase with Q5 Reaction Buffer 
following the manufacturer’s manual.  Cells from an individual B. subtilis colony were 
resuspended in 10 PL of water so that the water looked cloudy. The cells were incubated at 
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100 oC for 10 mins, and subsequently frozen at -80 oC for 5 mins before thawing at room 
temperature.  2.5 PL of lysed cells were added per 25 PL PCR reaction. The gel-purified 
PCR products could then be sequenced. 
 
4.8.11 Isolations to test peptide production 
To test subtilin and subtilosin A production, the appropriate strains of Bacillus 
subtilis were grown in 5 mL of LB overnight at 37 °C with 200 rpm shaking for a starter 
culture.  The next morning, 50 mL of LB in a 250 mL Erlenmeyer flask was inoculated with 
50 PL of the starter culture and grown at 37 °C with 200 rpm shaking for 30 hours. Cells 
were pelleted at 4,000 rpm for 25 mins, and decanted before being resuspended in 1.0 mL of 
methanol and transferred to an Eppendorf tube.  The cells were allowed to sit at rt for 1 hour 
for extraction. Cells were pelleted again at 15,000 rpm for 5 mins and the resulting methanol 
supernatant was diluted 1:10 in 1:1 acetonitrile:water for injection on the LCMS. The 
supernatants were also extracted by clean-up over a Waters C18 Sep Pak cartridge according 
to the manufacturer’s manual.  The cartridge was pre-equilibrated with 10 mL of methanol, 
then 10 mL of water.  The supernatant was pumped over the pre-equilibrated cartridge with a 
60 mL syringe.  The cartridge was washed with 10 mL of water before eluting with 5 mL 
methanol.  The extracts were diluted 1:10 in 1:1 acetonitrile:water for injection on the 
LCMS.  
 
4.8.12 LCMS 
LCMS data were acquired on an Agilent 6520 Accurate-Mass Q-TOF mass 
spectrometer with an electrospray-ionization source in positive ion mode. The drying gas 
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temperature was 350 °C, and the fragmentor voltage was 250 V. The peptides were separated 
by using a reverse-phase kinetex column; acetonitrile with 0.1% formic acid was run as a 
gradient from 2% to 100% over 15 min and held at 100% for 2 min against water with 0.1% 
formic acid.  
4.8.13 GFP Fluorescence Assay 
To monitor unnatural amino acid incorporation, GFP expression was carried out by 
first growing the appropriate Bacillus subtilis strains in 5 mL of LB overnight at 37 °C with 
200 rpm shaking for a starter culture.  The next morning, 50 mL of LB in a culture tube was 
inoculated with 50 PL of the starter culture and grown at 37 °C with 200 rpm shaking until 
OD600 reached 0.6. Cells were divided into 5 mL aliquots in culture, depending on the 
number of samples needed, and the unnatural amino acid was added from a 100 mM stock in 
0.1 M NaOH to a final concentration of 1 mM.  The cultures were then grown at 37 °C with 
200 rpm shaking for 7 hrs.  Cells were pelleted at 4,000 rpm for 5 mins, and decanted.   
To visualize GFP, the cells were first lysed by freezing at -80 °C and thawing at rt.  
Then the cells were resuspended in 100 mM KHPO4 buffer at pH 7.0, transferred to an 
Eppendorf tube, and incubated with 125 Pg/mL lysozyme at 37 °C with 200 rpm shaking for 
30 mins.  Cells were pelleted again at 15,000 rpm for 10 mins, and 200 PL of the resulting 
clarified lysate was transferred to a 96-well plate with clear bottom.  GFP was measured on 
Molecular Devices SpectraMax GeminiEM fluorescence plate reader with a 490 nm 
excitation wavelength and 510 nm emission wavelength. 
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CHAPTER V 
CONCLUSION 
 
In this work, we focused on studying the biosynthetic potential of the understudied 
bacterial genus, Bacillus.  We looked for natural products that would impact biofilm 
formation in our model organism, Bacillus subtilis, and discovered that thiocillin induced B. 
subtilis to produce biofilm. Next, we did extensive bioinformatics analysis of over 1,500 
Bacillus genomes, and uncovered a set of highly-conserved natural product biosynthetic 
pathways and a set of unique, ‘singleton’ biosynthetic pathways.  To access these new 
pathways, we developed a heterologous expression platform that allows us to rapidly move 
entire biosynthetic pathways into the host organisms, Bacillus subtilis.   
Natural products can act as antibiotics as well as signaling molecules for 
communication between bacteria that alter gene expression and development.  We used a 
combination of coculture, fluorescent transcriptional reporter assays, and MALDI-TOF IMS 
to identify and characterize the thiocillins, and the broader thiopeptide family, as chemical 
signals that induce biofilm formation in Bacillus subtilis.  We showed that this occurs 
independently of the thiocillin’s antibiotic activity in a kinD-independent fashion.  Structure-
activity relationship studies showed a complete loss of activity when major structural 
modifications were made to the thiocillin scaffold, indicating key components of these 
scaffolds are necessary to induce gene expression. Additionally, we used bioinformatics tools 
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to identity putative thiopeptide biosynthetic pathways in other species of Bacillus. We tested 
two of them (Bacillus atrophaeus 1942 and Bacillus sp. 107) for their ability to induce 
biofilm formation. Both strains induced biofilm gene expression, but only Bacillus 
atrophaeus did so in a kinD-independent manner.  Finally, we designed and synthesized 
thiocillin analogs for pull-down assays to determine thiocillin’s binding partner and further 
understand its mechanism of action.  We took a chemoenzymatic approach to synthesize the 
probes, which involved SPPS to produce a linear version of thiocillin with a T4V mutation 
and propargyl glycine inserted at the T3 or T13 position. We utilized the biorthogonal 
CuAAC reaction to attach a photo-crosslinking probe, and confirmed it was still able to 
induce biofilm formation in Bacillus subtilis.  
We pursued an intensive bioinformatics analysis of the genus Bacillus to measure its 
chemical diversity and better understand the role of its specialized metabolites. By examining 
1,566 genomes, we have evaluated nearly five times more sequences than the previously 
published analysis of the Bacillus genus.  This depth of sequence information gave us more 
insights than what we could have gleaned from a smaller population. The results of our 
analysis indicate Bacilli have the biosynthetic machinery for a set of characteristic, highly 
conserved compounds across the genus or within individual groups.  These compounds play 
either known or currently unknown roles in signaling and bacterial development within 
Bacilli and across interspecies interactions.  We were also able to discover a set of highly-
conserved pathways whose products are unknown, and that we hypothesize are important 
signals for Bacilli. In addition to highly conserved BGCs, we also identified a number of 
unique, weakly conserved BGCs scattered across all species and BGC classes. The majority 
of these BGCs seem to have been acquired through horizontal gene transfer. The unique 
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BGCs are quite diverse and offer leads for identifying new, distinct natural products that 
could occupy new chemical space and exhibit previously unknown biological activities.  
We looked at the highly-conserved, unknown biosynthetic pathway that encodes the 
Type III PKS, alkylpyrone, to answer questions about its function in Bacillus development.  
Based on expression data and similarity to the known germicidin compounds from 
Streptomycetes, we hypothesized that the alkylpyrones might have a role in sporulation.  We 
tested two alkylpyrone compounds for biological activity in sporulation and both delayed the 
onset of sporulation.  Other compounds that have been shown to delay sporulation also cause 
cell lysis and death. Thus, the alkylpyrones are the first identified specialized metabolite that 
delays the process of sporulation without inhibiting growth.  
To access the new pathways identified in our bioinformatics analysis, we developed a 
heterologous expression platform to rapidly move entire biosynthetic pathways into the host 
organism, Bacillus subtilis.  Developing simplified and robust platforms for the identification 
of new cryptic gene clusters is imperative for the pursuit of new antibiotics. Using a Bacillus 
based platform allows for rapid cloning and expression of peptides, and circumvents many 
challenges in the field.  Bacillus is fast-growing, safe, codon-flexible, highly 
recombinogenic, and naturally competent.  We established a streamlined cloning strategy that 
uses Gibson assembly to stitch together entire biosynthetic pathways with regions of 
homology to the Bacillus subtilis genome.  We could then take advantage of the highly 
recombinogenic nature of Bacillus subtilis through direct double homologous recombination 
of the linear Gibson reaction product into the genome of B. subtilis.  
To further improve our host, we engineered various Bacillus subtilis strains that could 
be disseminated for general use in heterologous expression. First, we generated a more 
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competent host for more efficient transformation of large assemblies of DNA. Next, to 
reduce metabolic burden on the host and provide a cleaner background for characterization, 
we did a systematic knock-out of specialized metabolite natural product pathways from the 
hyper-competent and a protease-deficient Bacillus subtilis hosts.  
With our B. subtilis hosts in hand, we used our cloning strategy to rearrange and 
heterologously express two Bacillus natural products. Subtilosin A and subtilin are known 
natural products from two different families of RiPPs biosynthetic pathways.  We designed 
our strategy so that we moved the structural gene to a different, neutral site in the B. subtilis 
genome to facilitate subsequent mutations to the natural product.  To further expand the 
capabilities of our heterologous platform, we were able to incorporate unnatural amino acids 
in a GFP protein in Bacillus subtilis, allowing us to add new chemical functionalities or 
useful handles for various assays. We have developed tools that will enable future efforts to 
discover, characterize, and modify natural product antibiotics in Bacillus subtilis. 
Discovery of new antibiotics is crucial with the continuing rise of antibiotic resistance 
to current therapeutics. Natural products are a rich source of novel compounds for antibiotic 
development that can help abate this crisis.  One understudied source for new natural product 
antibiotics is the genus, Bacillus. The combination of our depth of knowledge of its 
biosynthetic potential and the genetic utility of the model organism, Bacillus subtilis, make 
natural product discovery from Bacillus an attractive option. The work we have done 
developing Bacillus as a heterologous platform, including biosynthetic analysis, biological 
activity studies, and heterologous expression and manipulation, further promote Bacillus as a 
viable option for drug discovery research.  
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APPENDIX A.1: LCMS OF PURIFIED THIOPEITDES 
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APPENDIX A.2: IMAGES OF FLUORESCENT COLONIES 
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APPENDIX B: SPECTRA FOR CHAPTER 3 
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